var title_f21_31_22000="Doppler tricuspid regurgitation";
var content_f21_31_22000=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67929&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Tricuspid regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 174px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The color flow Doppler of a patient with mild tricuspid regrugitation (TR) due to moderate pulmonary hypertension shows a TR jet; although the jet entrains along the interatrial septum (IAS), it has a narrow vena contracta and proximal acceleration region (PISA), suggesting that TR is mild (panel A). Panel P is a continuous wave (cw) Doppler which shows that the jet is low density, has an incomplete envelope, and a parabolic shape. These features of mild tricuspid insufficiency co-exist with and are unaffected by pulmonary hypertension. Pulmonary hypertension is identified by a peak TR velocity of 3.7 meter/sec.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22000=[""].join("\n");
var outline_f21_31_22000=null;
var title_f21_31_22001="Prolymphocytic leukemia";
var content_f21_31_22001=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F58721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F58721&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Peripheral blood smear in a patient with prolymphocytic leukemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral blood smear from a 71-year-old male patient with splenomegaly and a white blood cell count of 50,000/&micro;L, with a preponderance of prolymphocytes. The prolymphocytes shown here are large cells with a moderate amount of clear to lightly basophilic cytoplasm, coarse nuclear chromatin, and a prominent single nucleolus (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22001=[""].join("\n");
var outline_f21_31_22001=null;
var title_f21_31_22002="Patient information: Gas and bloating (The Basics)";
var content_f21_31_22002=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15428\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"          Colonoscopy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/24/25986\">",
"         Patient information: Stomach ache and stomach upset (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?6/14/6371\">",
"         Patient information: Gas and bloating (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Gas and bloating (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/gas-and-bloating-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H461564074\">",
"      <span class=\"h1\">",
"       What are gas and bloating?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Gas is air that comes out of your body. It can come out of your anus and sometimes smells bad. It can also come out of your mouth as a burp. Bloating is the feeling of fullness and cramping in the belly that can happen with gas.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564081\">",
"      <span class=\"h1\">",
"       What causes gas?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Causes of gas include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Swallowing air, often while eating or drinking. Swallowed air usually comes back out as a burp.",
"       </li>",
"       <li>",
"        Eating certain foods, such as beans, broccoli, fruit, wheat, potatoes, corn, and noodles. Bacteria in the intestines digest parts of these foods and spit out gas.",
"       </li>",
"       <li>",
"        Trouble digesting certain foods, such as wheat or dairy products",
"       </li>",
"       <li>",
"        Conditions that harm the digestive system",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564088\">",
"      <span class=\"h1\">",
"       What causes bloating?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The colon has a lot of bends in it (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). When air gets trapped in these bends, you might feel cramps or sharp pains. This pain is common in the middle and top of the belly on either side.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564095\">",
"      <span class=\"h1\">",
"       How much gas is normal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people pass gas through the anus 14 to 23 times each day. Burping before and after meals is also common. Gas bothers some people more than others.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564102\">",
"      <span class=\"h1\">",
"       Why does my gas smell?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most of the gas that comes out of your anus has no smell. But some of it contains a substance called sulfur. Sulfur smells bad to most people.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564109\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to get rid of gas and bloating?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You might feel better if you:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Cut down on certain foods. Write down what you eat so you can figure out which foods are causing your gas. Everyone&rsquo;s body is different. Common causes of gas are:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Milk and dairy products",
"       </li>",
"       <li>",
"        Beans",
"       </li>",
"       <li>",
"        Some vegetables, such as cabbage, Brussels sprouts, asparagus, broccoli, potatoes, and corn",
"       </li>",
"       <li>",
"        Some whole grains, such as wheat",
"       </li>",
"       <li>",
"        Most types of fruit",
"       </li>",
"       <li>",
"        Artificial sweeteners",
"       </li>",
"       <li>",
"        Soda and other fizzy drinks",
"       </li>",
"       <li>",
"        Chewing gum",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Take medicines that contain",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?5/43/5812?source=see_link\">",
"         simethicone",
"        </a>",
"        (sold as Maalox&reg; Anti-Gas, Mylanta&reg; Gas, Gas-X&reg;, or Phazyme&reg;). You can get these at a drug store. Simethicone breaks up gas bubbles in your intestines. Doctors aren&rsquo;t sure how well it works.",
"       </li>",
"       <li>",
"        Take a product called",
"        <a class=\"drug drug_general\" href=\"UTD.htm?26/13/26834?source=see_link\">",
"         Beano",
"        </a>",
"        . This can help your body digest beans and some vegetables.",
"       </li>",
"       <li>",
"        Take a medicine called bismuth subsalicylate (sold as Pepto-Bismol&reg;). This can help make gas smell less bad.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564116\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;See your doctor or nurse if you also have any of these symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Diarrhea that lasts longer than 5 days",
"       </li>",
"       <li>",
"        Unexplained weight loss",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Blood in bowel movements",
"       </li>",
"       <li>",
"        Loss of appetite",
"       </li>",
"       <li>",
"        Unexplained fever",
"       </li>",
"       <li>",
"        Throwing up for longer than 2 days (48 hours)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564123\">",
"      <span class=\"h1\">",
"       Are there tests I should have?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse will decide which tests you should have based on your age, other symptoms, and individual situation. There are lots of tests, but you may not need any.",
"     </p>",
"     <p>",
"      Here are the most common tests doctors use to find the cause of gas and bloating:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Tests on a sample of your bowel movements to check for blood, unusual levels of fat, and other things",
"       </li>",
"       <li>",
"        Blood test to see if your body has trouble digesting an ingredient called gluten. Gluten is in bread, pasta, condiments and other foods.",
"       </li>",
"       <li>",
"        Breath test to see if your body has trouble digesting dairy products",
"       </li>",
"       <li>",
"        X-rays to see if there is something wrong with your intestines",
"       </li>",
"       <li>",
"        Sigmoidoscopy or colonoscopy &ndash; For these tests, the doctor puts a thin tube into your anus. Then, he or she advances the tube into your colon. The tube has a camera attached to it, so the doctor can see inside you. The doctor can also take samples of tissue to look at under the microscope (",
"        <a class=\"graphic graphic_figure graphicRef52258 \" href=\"UTD.htm?4/46/4834\">",
"         figure 2",
"        </a>",
"        ).",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564130\">",
"      <span class=\"h1\">",
"       How is gas and bloating treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on what is causing your gas and bloating. Treatments may include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Changing what you eat and drink",
"       </li>",
"       <li>",
"        Changing how you eat and drink. Eating more slowly can help with burping.",
"       </li>",
"       <li>",
"        Using supplements to help you digest dairy products",
"       </li>",
"       <li>",
"        Taking medicines that you can buy at a drug store",
"       </li>",
"       <li>",
"        Taking medicines that your doctor prescribes",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564137\">",
"      <span class=\"h1\">",
"       Can gas be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can reduce your chances of getting gas again by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Staying away from foods and drinks that cause gas for you",
"       </li>",
"       <li>",
"        Taking",
"        <a class=\"drug drug_general\" href=\"UTD.htm?26/13/26834?source=see_link\">",
"         Beano",
"        </a>",
"        when you eat beans and some vegetables",
"       </li>",
"       <li>",
"        Taking supplements that help you digest dairy, if that is your problem",
"       </li>",
"       <li>",
"        Eating more slowly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H461564144\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=see_link\">",
"       Patient information: Stomach ache and stomach upset (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=see_link\">",
"       Patient information: Gas and bloating (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?21/31/22002?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15428 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22002=[""].join("\n");
var outline_f21_31_22002=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564074\">",
"      What are gas and bloating?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564081\">",
"      What causes gas?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564088\">",
"      What causes bloating?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564095\">",
"      How much gas is normal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564102\">",
"      Why does my gas smell?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564109\">",
"      Is there anything I can do on my own to get rid of gas and bloating?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564116\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564123\">",
"      Are there tests I should have?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564130\">",
"      How is gas and bloating treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564137\">",
"      Can gas be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H461564144\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15428\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/46/4834\">",
"       Colonoscopy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/14/6371?source=related_link\">",
"      Patient information: Gas and bloating (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/24/25986?source=related_link\">",
"      Patient information: Stomach ache and stomach upset (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_31_22003="Early diphtheritic membrane";
var content_f21_31_22003=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early-stage diphtheritic membrane on right tonsil of 26-year-old female patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 505px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kadirova R, Kartoglu HU, Strebel PM. Clinical characteristics and management of 676 hospitalized diphtheria cases, Kyrgyz Republic, 1995. J Infect Dis 2000; 181:S110. Copyright &copy; 2000 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22003=[""].join("\n");
var outline_f21_31_22003=null;
var title_f21_31_22004="Riluzole: Drug information";
var content_f21_31_22004=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Riluzole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?32/21/33108?source=see_link\">",
"    see \"Riluzole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F218370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Rilutek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F218371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Riluzole&reg;;",
"     </li>",
"     <li>",
"      Mylan-Riluzole;",
"     </li>",
"     <li>",
"      Rilutek&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F218406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Glutamate Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F218375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ALS treatment:",
"     </b>",
"     Oral: 50 mg every 12 hours; no increased benefit can be expected from higher daily doses, but adverse events are increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Dosage adjustment in smoking:",
"     </i>",
"     Cigarette smoking is known to induce CYP1A2; patients who smoke cigarettes would be expected to eliminate riluzole faster. There is no information, however, on the effect of, or need for, dosage adjustment in these patients.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F218376\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F218377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustments recommended by manufacturer; use caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F218378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No specific dosage adjustments recommended by manufacturer; use caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F218348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Rilutek&reg;: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F218333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F218351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer at the same time each day, at least 1 hour before or 2 hours after a meal.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F218350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of amyotrophic lateral sclerosis (ALS); riluzole can extend survival or time to tracheostomy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F218404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypertension (5%), peripheral edema (3%), tachycardia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (4%), somnolence (2%), vertigo (2%), malaise (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (4%), eczema (2%), exfoliative dermatitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (5%), vomiting (4%), flatulence (3%), oral moniliasis (1%), stomatitis (1%), tooth caries (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary tract infection (3%), dysuria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver function tests increased (8% &gt;3 x ULN; 2% &gt;5 x ULN)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (4%), paresthesia (circumoral; 2%), tremor (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Lung function decreased (10%), cough increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alkaline phosphatase increased, amblyopia, anaphylactoid reaction, anaphylaxis, angioedema, aplastic anemia, arthrosis, asthma, ataxia, bone necrosis, bradycardia, bundle branch block, cataract, cerebral hemorrhage, deafness, dementia, diabetes mellitus, diabetes insipidus, edema, erythema multiforme, extrapyramidal syndrome, facial paralysis, gastrointestinal hemorrhage, gastrointestinal ulcer, GGT increased, glaucoma, hallucination, heart failure, hematemesis, hematuria, hemoptysis, hepatitis, hypercalcemia, hypokalemia, hypokinesia, hyponatremia, hypotension, hypersensitivity pneumonitis, interstitial lung disease, jaundice, LDH increased, leukocytosis, leukopenia, lymphadenopathy, mania, myoclonus, neutropenia, osteoporosis, pancreatitis,  peripheral neuritis, pleural effusion, pseudomembranous colitis, purpura, respiratory acidosis, seizure, subarachnoid hemorrhage, thrombosis, urinary retention, urticaria, uterine hemorrhage, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F218354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe hypersensitivity reactions to riluzole or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F218337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause dizziness or somnolence; caution should be used performing tasks which require alertness (operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary disorders: Interstitial lung disease (primarily hypersensitivity pneumonitis) has occurred with riluzole therapy. May present as progressive dyspnea, cough, and/or chest pain; prompt evaluation and possible discontinuation of therapy may be necessary. Symptoms usually improve upon discontinuation of riluzole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neutropenia: Among 4000 patients given riluzole for ALS, there were 3 cases of marked neutropenia (ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ), all seen within the first 2 months of treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; do not administer if baseline liver function tests are elevated. May cause elevations in transaminases (usually transient) within first 3 months of therapy; discontinue if ALT levels are &ge;5 times upper limit of normal or if jaundice develops.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in the elderly; clearance decreased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Females: Use with caution in females; clearance decreased.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F218401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F218342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP1A2 Inducers (Strong): May increase the metabolism of CYP1A2 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cyproterone: May decrease the serum concentration of CYP1A2 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F218367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (due to CNS depression and possible risk of liver toxicity).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: A high-fat meal decreases absorption of riluzole (decreasing AUC by 20% and peak blood levels by 45%). Charbroiled food may increase riluzole elimination.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F218344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F218357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Impaired fertility, decreased implantation, increased intrauterine death, and adverse effects on offspring growth and viability were observed in animal studies. There are no adequate or well-controlled studies in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F218382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F218358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at least 1 hour before or 2 hours after a meal.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F218356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Rilutek Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (60): $1503.89",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F218346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor serum aminotransferases including ALT levels before and during therapy. Evaluate serum ALT levels every month during the first 3 months of therapy, every 3 months during the remainder of the first year and periodically thereafter. Evaluate ALT levels more frequently in patients who develop elevations. Maximum increases in serum ALT usually occurred within 3 months after the start of therapy and were usually transient when &lt;5 times ULN (upper limits of normal). Discontinue therapy if ALT levels are &ge;5 times upper limit of normal or if jaundice develops.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     In trials, if ALT levels were &lt;5 times ULN, treatment continued and ALT levels usually returned to below 2 times ULN within 2-6 months. There is no experience with continued treatment of ALS patients once ALT values exceed 5 times ULN.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F218359\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Laidec (TW);",
"     </li>",
"     <li>",
"      Rilutek (AR, AT, AU, BE, BO, BR, CH, CN, CO, CR, CZ, DE, DK, DO, EC, ES, FI, FR, GB, GR, GT, HK, HN, IE, IL, IT, KP, LU, MX, NI, NL, NO, PA, PE, PH, PL, PR, PT, PY, RU, SE, SV, TH, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Sclefic (BG);",
"     </li>",
"     <li>",
"      Xie Yi Li (CL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F218336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Mechanism of action is not known. Pharmacologic properties include inhibitory effect on glutamate release, inactivation of voltage-dependent sodium channels; and ability to interfere with intracellular events that follow transmitter binding at excitatory amino acid receptors",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F218353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: ~90%; high-fat meal decreases AUC by 20% and peak blood levels by 45%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding, plasma: 96%, primarily to albumin and lipoproteins",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic to six major and a number of minor metabolites via CYP1A2 dependent hydroxylation and glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Absolute: ~60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (90%; 85% as metabolites, 2% as unchanged drug) and feces (5%) within 7 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bensimon G, Lacomblez L, Meininger V, et al, &ldquo;A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. ALS/Riluzole Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1994, 330(9):585-91",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/31/22004/abstract-text/8302340/pubmed\" id=\"8302340\" target=\"_blank\">",
"        8302340",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wokke J, &ldquo;Riluzole,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1996, 348(9030):795-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/31/22004/abstract-text/8813989/pubmed\" id=\"8813989\" target=\"_blank\">",
"        8813989",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9865 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-15E18CE5C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22004=[""].join("\n");
var outline_f21_31_22004=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218370\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218371\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218406\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218375\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218376\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218377\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218378\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218348\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218333\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218351\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218350\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218404\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218354\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218337\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218401\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218342\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218367\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218344\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218357\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218382\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218358\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218356\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218346\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218359\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218336\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F218353\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9865\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9865|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?32/21/33108?source=related_link\">",
"      Riluzole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_31_22005="Folic acid: Pediatric drug information";
var content_f21_31_22005=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Folic acid: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"    see \"Folic acid: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=see_link\">",
"    see \"Folic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6813283\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Folacin-800 [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F173692\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Folic&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Nutritional Supplement",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vitamin, Water Soluble",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Enteral daily recommendations; adequate intake",
"     </b>",
"     (Vanek, 2012): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: 25-50 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Full-term neonates: 65 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Parenteral nutrition, maintenance requirement of folic acid",
"     </b>",
"     (Vanek, 2012): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Premature neonates: 56 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Full-term neonates: 140 mcg/day",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"      see \"Folic acid: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Adequate intake (AI):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing presented as dietary folate equivalents (DFE) to adjust for ~50% decreased bioavailability of food folate compared with that of folic acid supplement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1-6 months: 65 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     7-12 months: 80 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Dosing presented as dietary folate equivalents (DFE) to adjust for ~50% decreased bioavailability of food folate compared with that of folic acid supplement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     1-3 years: 150 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     4-8 years: 200 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     9-13 years: 300 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &ge;14 years: 400 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia (folic acid deficiency); treatment:",
"     </b>",
"     Oral, I.M., I.V., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: 0.1 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &lt;4 years: Up to 0.3 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children &gt;4 years and Adolescents: 0.4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Parenteral nutrition, maintenance requirement of folic acid",
"     </b>",
"     (Vanek, 2012): I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Infants: 56 mcg/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Children and Adolescents &le;13 years: 140 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Adolescents &ge;14 years: 400 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Gingival hyperplasia due to phenytoin, prevention:",
"     </b>",
"     Limited data available: Children &ge;6 years and Adolescents: 0.5 mg/day was used in a double-blind, randomized, placebo-controlled trial of 120 pediatric patients (treatment arm, n=62; age range: 6-15 years) who were started on phenytoin therapy within the last month for a seizure disorder; results showed a statistically significant difference in development of hyperplasia (treatment arm: 21% vs placebo: 88%); severity of cases less in treatment arm than placebo; study duration: 6 months (Arya, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Recommended daily allowance (RDA):",
"     </b>",
"     Expressed as dietary folate equivalents: Oral: 400 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pregnancy: 600 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Lactation: 500 mcg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Anemia (folic acid deficiency); treatment:",
"     </b>",
"     Oral, I.M., I.V., SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Nonpregnant and nonlactating adults: 0.4 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Pregnant and lactating women: 0.8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Prevention of neural tube defects:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Females of childbearing potential: 400-800 mcg/day (USPSTF, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Females at high-risk or with family history of neural tube defects: 4 mg/day (ACOG, 2003)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F173671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium folate: 5 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 0.4 mg, 0.8 mg, 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Folacin-800: 0.8 mg [scored; gluten free, sugar free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F173657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May be administered without regard to meals",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., SubQ: May administer undiluted deep I.M. or SubQ",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V.: May administer doses &le;5 mg undiluted over &ge;1 minute",
"     <b>",
"      or",
"     </b>",
"     may dilute &le;5 mg in 50 mL of NS or D",
"     <sub>",
"      5",
"     </sub>",
"     W (maximum concentration: 0.1 mg/mL) and infuse over 30 minutes. May also be added to I.V. maintenance solutions and given as an infusion.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F173739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, NS, fat emulsion 10%;",
"     <b>",
"      incompatible",
"     </b>",
"     with D",
"     <sub>",
"      40",
"     </sub>",
"     W, D",
"     <sub>",
"      50",
"     </sub>",
"     W. Do not use with oxidizing and reducing agents or heavy metal ions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Famotidine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Doxapram.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Magnesium sulfate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F16225651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of megaloblastic and macrocytic anemias due to folate deficiency (FDA approved in all ages); has also been used as a dietary supplement to prevent neural tube defects and prevention of gingival hyperplasia due to phenytoin",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F173740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Folic acid may be confused with folinic acid",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F173738\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Flushing (slight)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Malaise (general)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Erythema, pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to folic acid or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F16225650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with depressed hematopoiesis, alcoholism, and deficiencies of other vitamins; resistance to treatment with  folic acid may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The parenteral product contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal dysfunction. Premature neonates are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4-5 mcg/kg/day is associated with CNS and bone toxicity and tissue loading may occur at lower doses.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Folic acid doses &gt;0.1 mg may mask the hematologic effects of B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency, thus obscuring the diagnosis of pernicious anemia while allowing the neurologic complications due to B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency to progress; folic acid is not appropriate for monotherapy for treatment of pernicious, aplastic, or normocytic  anemias when anemia is present with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Folic acid injection contains benzyl alcohol (1.5%) as preservative, which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse; use caution with injection in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein-binding sites",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F173665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May decrease the serum concentration of Folic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Folic Acid may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F173668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F173683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Water soluble vitamins cross the placenta. Folate requirements increase during pregnancy. Folate supplementation during the periconceptual period decreases the risk of neural tube defects. Folate supplementation (doses larger than the RDA) is recommended for women who may become pregnant (IOM, 1998).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1058801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Total folate: Normal: 5-15 ng/mL; folate deficiency: &lt;5 ng/mL; megaloblastic anemia: &lt;2 ng/mL",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Folic acid is necessary for formation of a number of coenzymes in many metabolic systems, particularly for purine and pyrimidine synthesis; required for nucleoprotein synthesis and maintenance in erythropoiesis; stimulates WBC and platelet production in folate deficiency anemia",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maximum effect: Oral: Within 30-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058807\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: In the proximal part of the small intestine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: Folic acid supplement: ~100%; in presence of food: 85%; Dietary folate: 50%  (IOM, 1999)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Trace amounts of unchanged drug in urine; 90% of dose as metabolites",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1058809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary folate equivalents (DFE)  is used to adjust for ~50% decreased bioavailability of food folate compared with that of folic acid supplement:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1 mcg DFE = 0.6 mcg folic acid from fortified food or as a supplement taken with meals, or",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     1 mcg DFE of food folate = 0.5 mcg of a supplement taken on an empty stomach",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     As of January 1998, the FDA has required manufacturers of enriched flour, bread, corn meal, pasta, rice, and other grain products to add folic acid to their products. The intent is to help decrease the risk of neural tube defects by increasing folic acid intake. Other foods which contain folic acid include dark green leafy vegetables, citrus fruits and juices, and lentils.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F173677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL folic acid oral solution may be made with tablets. Heat 90 mL of purified water almost to boiling. Dissolve parabens (methylparaben 200 mg and propylparaben 20 mg) in the heated water; cool to room temperature. Crush one-hundred 1 mg tablets, then dissolve folic acid in the solution. Adjust pH to 8-8.5 with sodium hydroxide 10%; add sufficient quantity of purified water to make 100 mL; mix well. Stable for 30 days at room temperature (Allen, 2007).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 0.05 mg/mL folic acid oral solution may be prepared using the injectable formulation (5 mg/mL). Mix 1 mL of injectable folic acid with 90 mL of purified water. Adjust pH to 8-8.5 with sodium hydroxide 10%; add sufficient quantity of purified water to make 100 mL; mix well. Stable for 30 days at room temperature (Nahata, 2004).",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV Jr, \"Folic Acid 1-mg/mL Oral Liquid,\"",
"     <i>",
"      Int J Pharm Compound",
"     </i>",
"     , 2007, 11(3):244.",
"    </div>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Practice Bulletins, \"Clinical Management Guidelines for Obstetrician-Gynecologists. Number 44, July 2003 (Replaces Committee Opinion Number 252, March 2001),\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2003, 102(1):203-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/31/22005/abstract-text/12850637/pubmed\" id=\"12850637\" target=\"_blank\">",
"        12850637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Arya R, Gulati S, Kabra M, et al, \"Folic Acid Supplementation Prevents Phenytoin-Induced Gingival Overgrowth in Children,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2011, 76(15):1338-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/31/22005/abstract-text/21482950/pubmed\" id=\"21482950\" target=\"_blank\">",
"        21482950",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Department  Health &amp; Human Services, Food Drug Administration, \"Aluminum in Large and Small Volume Parenterals Used in Total Parenteral Nutrition,\"",
"      <i>",
"       Federal Register",
"      </i>",
"      , 2000, 65(17):4103-11.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B",
"      </i>",
"      <sub>",
"       12",
"      </sub>",
"      <i>",
"       , Pantothenic Acid, Biotin and Choline",
"      </i>",
"      , Washington, DC: National Academy Press, 1998.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      U.S. Preventive Services Task Force (USPSTF), \"Folic Acid for the Prevention of Neural Tube Defects: U.S. Preventive Services Task Force Recommendation Statement,\"",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(9):626-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/31/22005/abstract-text/19414842/pubmed\" id=\"19414842\" target=\"_blank\">",
"        19414842",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanek VW, Borum P, Buchman A, et al, \"A.S.P.E.N. Position Paper: Recommendations for Changes in Commercially Available Parenteral Multivitamin and Multi-trace Element Products,\"",
"      <i>",
"       Nutr Clin Pract",
"      </i>",
"      , 2012, 27(4):440-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?21/31/22005/abstract-text/22730042/pubmed\" id=\"22730042\" target=\"_blank\">",
"        22730042",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13322 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22005=[""].join("\n");
var outline_f21_31_22005=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6813283\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173692\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058799\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442542\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058794\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173671\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173657\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058803\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173739\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225651\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058802\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173740\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173738\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058808\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16225650\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058793\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299358\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173665\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173668\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173683\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058798\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058801\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058792\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058806\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058807\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058809\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F173677\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13322\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13322|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=related_link\">",
"      Folic acid: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/57/25492?source=related_link\">",
"      Folic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_31_22006="Hepatobiliary manifestations of inflammatory bowel disease";
var content_f21_31_22006=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hepatobiliary manifestations of inflammatory bowel disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22006/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22006/contributors\">",
"     Gad Friedman, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22006/contributors\">",
"     Alain Bitton, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22006/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22006/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22006/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22006/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/31/22006/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diseases of the liver and biliary tract are common extraintestinal manifestations of inflammatory bowel disease (IBD) (",
"    <a class=\"graphic graphic_table graphicRef78606 \" href=\"UTD.htm?11/49/12059\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Primary sclerosing cholangitis (PSC) is one of the more common hepatobiliary complications of IBD, particularly in patients with ulcerative colitis. It is estimated that approximately 5 percent of patients with ulcerative colitis develop PSC and that ulcerative colitis is present in up to 90 percent of patients with PSC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Abnormal liver biochemical tests are present in up to 30 percent of patients with IBD and do not appear to correlate with disease activity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/5\">",
"     5",
"    </a>",
"    ]. As a result, persistently abnormal liver biochemical tests should generally be evaluated. This topic review will focus upon the other hepatobiliary manifestations that can occur in patients with IBD. The association of IBD with PSC is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\", section on 'PSC and inflammatory bowel disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DRUG-INDUCED HEPATOTOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the drugs used in the medical management of inflammatory bowel disease (IBD) have been associated with liver toxicity, although the overall incidence of serious complications is low [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The following are among the reactions that can be seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      can cause both hepatocellular and cholestatic enzyme abnormalities, often related to a hypersensitivity reaction. Newer sulfa-free aminosalicylate preparations deliver increased amounts of the pharmacologically active ingredient of sulfasalazine (5-ASA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      ) to the site of active bowel disease and are associated with a lower systemic toxicity. 5-ASA can rarely cause pancreatitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"       \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      can cause a spectrum of hepatic injury, ranging from asymptomatic aminotransferase elevations (in approximately 5 percent of patients) to cholestasis, veno-occlusive disease, and peliosis hepatis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       Mercaptopurine",
"      </a>",
"      (6-MP), a metabolite of azathioprine, can also cause hepatocellular and cholestatic hepatitis. Thus, patients treated with azathioprine or 6-MP should have their liver biochemistries monitored regularly. Liver abnormalities usually resolve after discontinuation of therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link&amp;anchor=H16#H16\">",
"       \"Immunomodulator therapy in Crohn's disease\", section on 'Toxicity'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A metabolite of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , 6-thioguanine (6-TG), has been evaluated as an alternative immunosuppressant in inflammatory bowel disease. Unfortunately, in one study, elevated liver enzymes were noted in 26 percent of patients on 6-TG [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/8\">",
"       8",
"      </a>",
"      ]. Nodular regenerative hyperplasia was found in 76 percent of liver biopsies of patients with liver enzyme abnormalities. In another study, nodular regenerative hyperplasia resulted in higher hepatic venous pressure gradients, causing clinically significant portal hypertension in some patients [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/9\">",
"       9",
"      </a>",
"      ]. Because of these findings the authors recommended that this agent should not be used as therapy for patients with IBD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37095?source=see_link\">",
"       \"Nodular regenerative hyperplasia of the liver\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      has been associated with macrovesicular steatosis, hepatic fibrosis, and cirrhosis in a cumulative dose response fashion. Routine liver biopsy has been advocated as a baseline and then after a cumulative dose of 1.5 to 2.0 gm. However, this recommendation has been challenged in light of the very low incidence of liver disease in patients with rheumatoid arthritis who, despite long-term use of methotrexate, are managed according to guidelines issued by the American College of Rheumatology [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/10\">",
"       10",
"      </a>",
"      ]. Alcohol is a risk factor for methotrexate-induced liver disease and patients should be counseled about strict avoidance of alcohol. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"       \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      has been associated with an increase in aminotransferases in patients with Crohn's disease. The increased ALT was usually less than twice the upper limit of normal and there is usually no clinical sequelae [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/11\">",
"       11",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"       \"Infliximab in Crohn's disease\"",
"      </a>",
"      .) However, there have been case reports of severe cholestatic liver disease related to infliximab. Two patients recovered upon cessation of infliximab while one patient required liver transplantation [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"      </a>",
"      .) Similarly, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , mild elevations in liver enzymes have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/15\">",
"       15",
"      </a>",
"      ]. In general, patients were asymptomatic; however, there are case reports of adalimumab-induced subacute liver failure and autoimmune hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STEATOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steatosis, or fatty liver disease, is seen in up to 50 percent of abnormal liver biopsies in patients with inflammatory bowel disease (IBD) . Patients often present with hepatomegaly. The etiology is probably multifactorial, with malnutrition and corticosteroids being of primary importance. Steatosis is often related to disease severity and may be reversed with treatment of the underlying IBD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link&amp;anchor=H9#H9\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\", section on 'Acute steatosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=see_link&amp;anchor=H13#H13\">",
"     \"Drugs and the liver: Patterns of drug-induced liver injury\", section on 'Chronic steatosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHOLELITHIASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gallstones are seen in 13 to 34 percent of patients with ileitis or ileal resection. Thus, an increased incidence occurs only in patients with Crohn's disease and not ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/17\">",
"     17",
"    </a>",
"    ]. They are probably caused by the malabsorption of bile acids, which interferes with their enterohepatic circulation. This leads to depletion of bile salts and the formation of lithogenic bile. There is no evidence that abnormal gallbladder emptying or contractility is a cause of stone formation in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/18\">",
"     18",
"    </a>",
"    ], although increased gallstone cholesterol concentrations have been identified in patients following ileoanal anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=see_link\">",
"     \"Epidemiology of and risk factors for gallstones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PERICHOLANGITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pericholangitis was once considered a separate entity. However, it is now thought to be a subset of primary sclerosing cholangitis, called small duct primary sclerosing cholangitis. The diagnosis should be suspected in patients with ulcerative colitis who have cholestatic liver function tests and normal large bile duct anatomy. Liver biopsy reveals periportal and periductular fibrosis with a benign mixed cellular infiltration of the portal tracts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary sclerosing cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GRANULOMATOUS HEPATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulomatous hepatitis is an uncommon but well recognized complication of Crohn's disease (",
"    <a class=\"graphic graphic_picture graphicRef64126 \" href=\"UTD.htm?18/3/18486\">",
"     picture 1",
"    </a>",
"    ). Its course is usually benign; the main manifestation is an increase in cholestatic enzymes such as alkaline phosphatase. It can also be caused by a variety of medications including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/6\">",
"     6",
"    </a>",
"    ]. Treatment, if necessary, includes the administration of corticosteroids and other immunosuppressive drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=see_link\">",
"     \"Hepatic granulomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HEPATIC AMYLOIDOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Secondary (reactive or AA) amyloidosis is seen in 0.9 percent of patients with Crohn's disease and in 0.07 percent with ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/20\">",
"     20",
"    </a>",
"    ]. It is more common in men with colonic involvement. There seems to be no relationship to suppurative complications, extraintestinal manifestations, or duration or extent of disease. The amyloid deposits can involve almost any organ, including the liver, resulting in asymptomatic hepatomegaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=see_link\">",
"     \"Gastrointestinal amyloidosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Optimal therapy consists of controlling the inflammatory component of the Crohn's disease, thereby decreasing the release of the acute phase reactant serum amyloid A which is the precursor of the amyloid fibrils in this condition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=see_link\">",
"     \"Pathogenesis of secondary (AA) amyloidosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=see_link\">",
"     \"Treatment of secondary (AA) amyloidosis\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     Colchicine",
"    </a>",
"    has been used to treat systemic amyloidosis in a few cases with some success [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LIVER ABSCESS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liver abscesses related to Crohn's disease primarily occur in individuals with a known history of inflammatory bowel disease (IBD), although they can be the initial manifestation of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/22\">",
"     22",
"    </a>",
"    ]. Patients present with fever, with or without abdominal pain, jaundice, diarrhea or hepatomegaly. Leukocytosis and elevated serum alkaline phosphatase concentrations are the most common laboratory abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=see_link\">",
"     \"Pyogenic liver abscess\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanism of abscess formation is unclear. It may be due to direct extension of intraabdominal abscesses or possibly due to portal pyemia with secondary seeding in the liver parenchyma. Successful management requires both drainage of the liver abscess, which can be performed percutaneously under radiologic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/23\">",
"     23",
"    </a>",
"    ] and treatment of the underlying Crohn's disease.",
"   </p>",
"   <p>",
"    The same mechanism may also be important for the development of rare but potentially life-threatening portal vein thrombosis associated with IBD. Successful use of anticoagulation or thrombolytic therapy has been reported in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PANCREATITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatitis is a rare extraintestinal manifestation of inflammatory bowel disease (IBD) that can result from duodenal fistulas, ampullary Crohn's disease, gallstones, primary sclerosing cholangitis, drugs such as 6-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"     mercaptopurine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , or very rarely 5-ASA agents, autoimmune pancreatitis, and primary Crohn's disease of the pancreas. In one study, drugs (mainly azathioprine and 6-mercaptopurine) were the leading cause of pancreatitis in Crohn's disease, and patients with Crohn's disease were noted to be at a higher risk for azathioprine and 6-mercaptopurine associated acute pancreatitis than patients treated with these drugs for other causes [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PRIMARY BILIARY CIRRHOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary biliary cirrhosis (PBC) is a disease characterized by progressive inflammatory destruction of interlobular and septal bile ducts that results in cholestasis and cirrhosis with a strong association with antimitochondrial antibodies. There are multiple case reports of PBC in ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. The autoimmune features of both diseases and their common association with some HLA haplotypes suggest a similar genetic predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22006/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory bowel disease (IBD) can be associated with a variety of hepatobiliary manifestations.",
"     </li>",
"     <li>",
"      Most of the drugs used in the medical management of IBD have been associated with liver toxicity.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       Sulfasalazine",
"      </a>",
"      can cause both hepatocellular and cholestatic enzyme abnormalities, often related to a hypersensitivity reaction.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      can cause asymptomatic aminotransferase elevations, cholestasis, veno-occlusive disease, and peliosis hepatis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/43/37559?source=see_link\">",
"       Mercaptopurine",
"      </a>",
"      (6-MP) can also cause hepatocellular and cholestatic hepatitis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      has been associated with macrovesicular steatosis, hepatic fibrosis, and cirrhosis in a cumulative dose response fashion.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       Infliximab",
"      </a>",
"      has been associated with an increase in aminotransferases (less than twice the upper limit of normal) in patients with Crohn's disease and usually has no clinical sequelae. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Drug-induced hepatotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Steatosis, or fatty liver disease, is seen in up to 50 percent of abnormal liver biopsies in patients with IBD. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Steatosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other less frequent hepatobiliary",
"      <span class=\"nowrap\">",
"       manifestations/associations",
"      </span>",
"      of IBD include gallstones, pericholangitis, granulomatous hepatitis, hepatic amyloidosis, liver abscess, and primary biliary cirrhosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Cholelithiasis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pericholangitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Granulomatous hepatitis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Hepatic amyloidosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Liver abscess'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Primary biliary cirrhosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      These conditions should be considered in patients with IBD who present with clinical or laboratory features suggestive of hepatobiliary involvement. Evaluation should be based upon the clinical setting and suggestive clinical or laboratory features.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/1\">",
"      Raj V, Lichtenstein DR. Hepatobiliary manifestations of inflammatory bowel disease. Gastroenterol Clin North Am 1999; 28:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/2\">",
"      Riegler G, D'Inc&agrave; R, Sturniolo GC, et al. Hepatobiliary alterations in patients with inflammatory bowel disease: a multicenter study. Caprilli &amp; Gruppo Italiano Studio Colon-Retto. Scand J Gastroenterol 1998; 33:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/3\">",
"      Wewer V, Gluud C, Schlichting P, et al. Prevalence of hepatobiliary dysfunction in a regional group of patients with chronic inflammatory bowel disease. Scand J Gastroenterol 1991; 26:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/4\">",
"      Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/5\">",
"      Mendes FD, Levy C, Enders FB, et al. Abnormal hepatic biochemistries in patients with inflammatory bowel disease. Am J Gastroenterol 2007; 102:344.",
"     </a>",
"    </li>",
"    <li>",
"     Stricker BH. Drug-Induced Hepatic Injury, 2nd ed, Elsevier, New York 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/7\">",
"      Gisbert JP, Luna M, Gonz&aacute;lez-Lama Y, et al. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/8\">",
"      Dubinsky MC, Vasiliauskas EA, Singh H, et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/9\">",
"      Ferlitsch A, Teml A, Reinisch W, et al. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol 2007; 102:2495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/10\">",
"      Kremer JM. Liver toxicity does not have to follow methotrexate therapy of patients with rheumatoid arthritis. Am J Gastroenterol 1997; 92:194.",
"     </a>",
"    </li>",
"    <li>",
"     Cot&eacute; T. TNF Blocker Safety: Lymphoma and Liver Failure. Federal Drug Administration, March 4, 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/12\">",
"      Tobon GJ, Ca&ntilde;as C, Jaller JJ, et al. Serious liver disease induced by infliximab. Clin Rheumatol 2007; 26:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/13\">",
"      Menghini VV, Arora AS. Infliximab-associated reversible cholestatic liver disease. Mayo Clin Proc 2001; 76:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/14\">",
"      Ierardi E, Della Valle N, Nacchiero MC, et al. Infliximab single administration followed by acute liver injury. Inflamm Bowel Dis 2006; 12:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/15\">",
"      Adar T, Mizrahi M, Pappo O, et al. Adalimumab-induced autoimmune hepatitis. J Clin Gastroenterol 2010; 44:e20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/16\">",
"      Hagel S, Bruns T, Theis B, et al. Subacute liver failure induced by adalimumab. Int J Clin Pharmacol Ther 2011; 49:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/17\">",
"      Parente F, Pastore L, Bargiggia S, et al. Incidence and risk factors for gallstones in patients with inflammatory bowel disease: a large case-control study. Hepatology 2007; 45:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/18\">",
"      Maurer P, Haag K, Roth M, et al. No evidence for abnormal gallbladder emptying in Crohn's disease. Hepatogastroenterology 1996; 43:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/19\">",
"      Mibu R, Makino I, Chijiiwa K. Gallstones and their composition in patients with ileoanal anastomosis. J Gastroenterol 1995; 30:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/20\">",
"      Greenstein AJ, Sachar DB, Panday AK, et al. Amyloidosis and inflammatory bowel disease. A 50-year experience with 25 patients. Medicine (Baltimore) 1992; 71:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/21\">",
"      Meyers S, Janowitz HD, Gumaste VV, et al. Colchicine therapy of the renal amyloidosis of ulcerative colitis. Gastroenterology 1988; 94:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/22\">",
"      Vakil N, Hayne G, Sharma A, et al. Liver abscess in Crohn's disease. Am J Gastroenterol 1994; 89:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/23\">",
"      Mir-Madjlessi SH, McHenry MC, Farmer RG. Liver abscess in Crohn's disease. Report of four cases and review of the literature. Gastroenterology 1986; 91:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/24\">",
"      Bermejo F, Lopez-Sanroman A, Taxonera C, et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment Pharmacol Ther 2008; 28:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/25\">",
"      Xiao WB, Liu YL. Primary biliary cirrhosis and ulcerative colitis: a case report and review of literature. World J Gastroenterol 2003; 9:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/26\">",
"      Koulentaki M, Koutroubakis IE, Petinaki E, et al. Ulcerative colitis associated with primary biliary cirrhosis. Dig Dis Sci 1999; 44:1953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/27\">",
"      Arai O, Ikeda H, Mouri H, et al. Two cases of inflammatory bowel disease diagnosed in the course of primary biliary cirrhosis. Nihon Shokakibyo Gakkai Zasshi 2010; 107:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/28\">",
"      Ohge H, Takesue Y, Yokoyama T, et al. Progression of primary biliary cirrhosis after proctocolectomy for ulcerative colitis. J Gastroenterol 2000; 35:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22006/abstract/29\">",
"      Onishi S, Sakamaki T, Maeda T, et al. DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 1994; 21:1053.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4074 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.81.197.98-C50D28AF5E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22006=[""].join("\n");
var outline_f21_31_22006=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DRUG-INDUCED HEPATOTOXICITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STEATOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHOLELITHIASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PERICHOLANGITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GRANULOMATOUS HEPATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HEPATIC AMYLOIDOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LIVER ABSCESS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PANCREATITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PRIMARY BILIARY CIRRHOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/4074\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4074|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/3/18486\" title=\"picture 1\">",
"      Granulomatous hepatitis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/4074|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/49/12059\" title=\"table 1\">",
"      Hepatobiliary diseases in IBD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/63/22521?source=related_link\">",
"      Clinical manifestations and diagnosis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/63/29690?source=related_link\">",
"      Drugs and the liver: Patterns of drug-induced liver injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/24/4489?source=related_link\">",
"      Epidemiology of and risk factors for gallstones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/63/12280?source=related_link\">",
"      Gastrointestinal amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/29/40406?source=related_link\">",
"      Hepatic granulomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/14/37095?source=related_link\">",
"      Nodular regenerative hyperplasia of the liver",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30086?source=related_link\">",
"      Pathogenesis of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29526?source=related_link\">",
"      Pyogenic liver abscess",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/53/23383?source=related_link\">",
"      Treatment of secondary (AA) amyloidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_31_22007="Sydenham chorea";
var content_f21_31_22007=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sydenham chorea",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22007/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/31/22007/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sydenham chorea (SC), also known as St. Vitus dance, St. Johannis' chorea, chorea minor, or rheumatic chorea, is one of the major clinical manifestations of acute rheumatic fever (ARF) and is the most common form of acquired chorea in childhood. It is a movement disorder characterized by chorea (involuntary brief, random and irregular movements of the limbs and face), emotional lability, and hypotonia.",
"   </p>",
"   <p>",
"    The incidence of ARF and SC has declined dramatically in the Western world [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/1\">",
"     1",
"    </a>",
"    ]. However, chorea is still a common manifestation of rheumatic fever, particularly in developing countries. In the United States, chorea was reported in 18 to 36 percent of cases of rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. Chorea also may occur as the initial manifestation of other illnesses, particularly systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other clinical manifestations of ARF and the approach to diagnosis of rheumatic fever are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although SC clearly is related to group A streptococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/7\">",
"     7",
"    </a>",
"    ], its pathogenesis is not completely understood. Molecular mimicry, in which antibodies directed against part of the group A streptococcus bacterium crossreact with host antigens in susceptible subjects, is thought to play an important role.",
"   </p>",
"   <p>",
"    In acute rheumatic fever, antibodies are mounted against N-acetyl-beta-D-glucosamine (NABG or GlcNAc), the immunodominant carbohydrate antigen of group A streptococci. These antibodies likely play a role in valvular injury in rheumatic carditis, and in other manifestations of ARF (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology and pathogenesis of acute rheumatic fever\", section on 'Molecular mimicry'",
"    </a>",
"    ). Different subsets of NABG antibodies appear to correlate with distinct clinical manifestations of ARF. In Sydenham chorea, the antibodies bind to lysoganglioside on the neuronal cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], where they are capable of triggering a signaling cascade [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/10\">",
"     10",
"    </a>",
"    ]. These antibodies also recognize the intracellular protein tubulin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/11\">",
"     11",
"    </a>",
"    ]. Tubulin-specific antibodies are not found in patients with acute rheumatic fever without SC, or in patients who have recovered from SC. The genes encoding these antibodies are similar to the genes encoding antibodies implicated in the pathogenesis of motor neuropathies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, tubulin appears to be an important neuronal target in the pathogenesis of Sydenham chorea.",
"   </p>",
"   <p>",
"    From a pathophysiologic viewpoint, the available data suggest involvement of the basal ganglia and cortical structures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In individual case reports, magnetic resonance imaging studies performed during and after an acute episode of SC demonstrated reversible abnormalities of the striatum [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/16\">",
"     16",
"    </a>",
"    ] and positron emission tomography and SPECT imaging showed striatal hypermetabolism and hyperperfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial presentation of SC typically occurs in patients between 5 and 13 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/19\">",
"     19",
"    </a>",
"    ]. Females are affected more frequently than males by a ratio of 2:1 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/19\">",
"     19",
"    </a>",
"    ]. Chorea appears to be less common in adults, particularly men [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SC appears to have a familial predisposition: a family history of rheumatic fever occurs in up to 30 percent of families with a history of chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurologic symptoms and signs",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to carditis and arthritis, which typically present within 21 days, the onset of chorea usually occurs one to eight months after the inciting infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/1\">",
"     1",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    ). The onset is typically insidious but may be abrupt. Emotional changes, such as easy crying or inappropriate laughing, may precede the development of chorea and, in some cases, deteriorating school performance is the initial concern.",
"   </p>",
"   <p>",
"    The chorea typically begins with distal movements of the hands, but generalized jerking of the face and feet may occur. The movements are rapid, irregular, and nonstereotypic jerks that are continuous while the patient is awake but improve with sleep. The chorea usually is generalized but may be more prominent on one side; 20 to 30 percent have hemichorea (ie, unilateral chorea) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/1,19-22\">",
"     1,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Motor symptoms, including ballismus, facial grimacing, and gross fasciculations of the tongue, often are observed in addition to frank chorea. These symptoms are associated with loss of fine motor control, muscle weakness, and hypotonia [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/19\">",
"     19",
"    </a>",
"    ]. In one review of 79 children with Sydenham chorea, handwriting changes were noted in 29 percent.",
"   </p>",
"   <p>",
"    Muscle weakness is best revealed by asking the patient to squeeze the examiner's hands; the pressure of the patient's grip increases and decreases continuously and capriciously, a phenomenon known as \"milkmaid's grip\" or \"milking sign.\" The hypotonia may be severe and the extremities may appear paretic. The cranial nerves are not involved, but speech often is abnormal and is described as \"jerky\" with sudden changes in pitch and loudness.",
"   </p>",
"   <p>",
"    Holding the arms outstretched may elicit \"spooning\" (hyperextension of the fingers with dorsiflexion of the wrist) or a \"pronator sign\" (supination of the extended pronated arm). No sensory loss occurs, and the deep tendon reflexes are unaffected except for delayed relaxation of the patellar reflex [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other neurologic complications are rare. Isolated cases of seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/24\">",
"     24",
"    </a>",
"    ], papilledema [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/25\">",
"     25",
"    </a>",
"    ], pseudotumor cerebri [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/26\">",
"     26",
"    </a>",
"    ], and blindness with central retinal artery occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/27\">",
"     27",
"    </a>",
"    ] have been ascribed to SC. Long-term neurologic consequences may include psychologic problems, tremor, mirror movements, poor coordination, and increased sensitivity to tics with the use of stimulant medication [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychiatric symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;SC is associated with a variety of psychiatric symptoms, including irritability; outbursts of inappropriate behavior, such as crying and restlessness; distractibility; and age-regressed behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/29\">",
"     29",
"    </a>",
"    ]. SC also appears to have a frequent association with obsessive-compulsive symptomatology [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. As an example, one report prospectively evaluated 50 children with rheumatic fever, 30 with and 20 without chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/31\">",
"     31",
"    </a>",
"    ]. Obsessive-compulsive symptoms occurred in 70 percent of the patients with chorea, but in none of those without chorea. Obsessive-compulsive disorder was diagnosed in 17 percent of the patients with chorea in this series and in 4 of 11 (35 percent) in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/29\">",
"     29",
"    </a>",
"    ]. These symptoms also may be seen in children with systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The psychiatric symptoms typically occur during the first two months of rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/31\">",
"     31",
"    </a>",
"    ]. Obsessive-compulsive symptoms can precede, occur concomitant with, or occur after the onset of chorea [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/31\">",
"     31",
"    </a>",
"    ]. The psychiatric symptoms tend to wax and wane with the motor symptoms. In rare cases, they are severe and can result in transient psychosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Association with other manifestations of rheumatic fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;SC often is seen without arthritis or carditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/5,20\">",
"     5,20",
"    </a>",
"    ]. In one series of 158 episodes of SC in 108 people in northern Australia, carditis was present in 28 percent and arthritis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    arthralgia in 17 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/5\">",
"     5",
"    </a>",
"    ]. Different results were noted in an outbreak of rheumatic fever in Utah between 1985 and 1986, in which chorea occurred in 28 percent of cases but was an isolated finding in only 4 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Echocardiographic studies have confirmed that subclinical carditis is common in patients with SC. In one series of 22 patients, carditis was detected by auscultation in five (23 percent); however, Doppler echocardiography detected silent mitral regurgitation in an additional nine patients, so that the total incidence of valvular involvement was 63 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14617?source=see_link\">",
"     \"Natural history, screening, and management of rheumatic heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SC is made clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/19\">",
"     19",
"    </a>",
"    ]. No specific laboratory test exists, and no abnormalities are found in the cerebrospinal fluid during an acute attack [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/4\">",
"     4",
"    </a>",
"    ]. The presence of carditis confirms the diagnosis, and a careful cardiac examination is mandatory. Mild cases of SC without other manifestations of rheumatic fever may be mistakenly ascribed to behavioral or emotional disorders or clumsiness [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/4\">",
"     4",
"    </a>",
"    ]. Other causes of chorea, including systemic lupus erythematosus and Huntington's disease must be excluded [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with pure chorea are afebrile and have little evidence of acute inflammation (eg, elevations in white blood cell count or acute phase reactants) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/5\">",
"     5",
"    </a>",
"    ]. Evidence of an active or recent group A beta hemolytic streptococcal infection is helpful but not always present. Throat cultures are often negative by the time chorea appears [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/5\">",
"     5",
"    </a>",
"    ], but an attempt should be made to isolate the organism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956332\">",
"    <span class=\"h2\">",
"     Streptococcal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Streptococcal antibodies are more useful because they indicate true infection rather than transient carriage, and, by measuring titers of several different antibodies, any significant recent streptococcal infection can be detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=see_link\">",
"     \"Clinical manifestations and diagnosis of acute rheumatic fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The antistreptolysin O titer is measured most commonly in suspected acute rheumatic fever. However, only 80 percent of patients with rheumatic fever show a rise in the antistreptolysin O titer, and low titers are common in children without rheumatic fever because of the prevalence of streptococcal infection. The antibody response peaks four to five weeks after the onset of pharyngitis, which typically is well before the appearance of chorea. The antideoxyribonuclease (anti-DNAse) B titer tends to remain elevated longer and may, therefore, be more sensitive in patients with chorea who typically present later [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of positive antibody tests was evaluated in the large series from northern Australia noted above [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/5\">",
"     5",
"    </a>",
"    ]. Among patients who were tested, the antistreptolysin O titer was elevated in 58 of 76 (76 percent) and the anti-DNAse B titer in 54 of 55 (98 percent); both titers were normal in only one patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956339\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other conditions are associated with chorea, including encephalitis, systemic lupus erythematosus, Wilson's disease, glutaric aciduria (type 2), Huntington disease, Tourette syndrome, familial benign chorea, thyrotoxicosis, and attention deficit disorder with choreiform movements, and should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/33\">",
"     33",
"    </a>",
"    ]. Diagnostic testing should include serum copper, ceruloplasmin, slit lamp examination, antinuclear antibodies, and a careful family history to identify Huntington chorea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=see_link\">",
"     \"Epidemiology and pathogenesis of Wilson disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H956346\">",
"    <span class=\"h2\">",
"     Imaging and echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have clinical, examination, and laboratory features of SC, neuroimaging usually does not provide additional information that assists in management decisions or determining prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/19\">",
"     19",
"    </a>",
"    ]. However, neuroimaging may be necessary to exclude other causes of chorea in patients with unusual histories, including those with hemichorea [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/19\">",
"     19",
"    </a>",
"    ]. Although not routinely done, positron emission tomography (PET) and single photon emission computer tomography (SPECT) may demonstrate abnormal basal ganglia metabolism or perfusion and may be helpful in patients who present with atypical clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/18,36\">",
"     18,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We perform electrocardiography and echocardiography on all patients with suspected SC, to evaluate for carditis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14617?source=see_link&amp;anchor=H16376507#H16376507\">",
"     \"Natural history, screening, and management of rheumatic heart disease\", section on 'Acute rheumatic fever'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sydenham chorea typically improves gradually, with a mean duration of 12 to 15 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Full recovery occurs in almost all patients, but symptoms occasionally persist for two years or more [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/5,21\">",
"     5,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy of chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with chorea should be treated when significant impairment of motor function and the possibility of self injury are present. Treatments reported to be effective include valproic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/39-41\">",
"     39-41",
"    </a>",
"    ], phenobarbital, haloperidol [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], pimozide [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/44\">",
"     44",
"    </a>",
"    ], diazepam, chlorpromazine, and carbamazepine [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/45\">",
"     45",
"    </a>",
"    ], corticosteroids [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/46-50\">",
"     46-50",
"    </a>",
"    ], plasma exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/51\">",
"     51",
"    </a>",
"    ], and intravenous immune globulin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. Haloperidol, a centrally acting drug, is effective in controlling chorea but may be associated with extrapyramidal reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/41\">",
"     41",
"    </a>",
"    ]. The efficacy of treatment with valproate and carbamazepine is not well established, because it is based on small uncontrolled case series, and in this setting drug effects may be difficult to distinguish from the spontaneous improvement observed in many cases of SC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/41,54\">",
"     41,54",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Corticosteroids may shorten the course of SC [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/41,46-50\">",
"     41,46-50",
"    </a>",
"    ]. The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for SC was assessed in a controlled trial in which 37 children and adolescents were randomly assigned to placebo or treatment with prednisone (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for four weeks followed by a gradual taper [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/49\">",
"     49",
"    </a>",
"    ]. Patients in both groups improved with time, but those in the prednisone group improved more rapidly (significant reduction in mean chorea intensity score at week 1 versus week 2 to 3), and earlier complete remission (54 versus 120 days). The occurrence of relapses was similar between groups. No severe adverse events were observed in the prednisone group.",
"   </p>",
"   <p>",
"    In a retrospective analysis of 68 children with SC, those who received a two-week course of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) followed by a gradual taper had a shorter duration of chorea than did those who were untreated (three versus ten weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/50\">",
"     50",
"    </a>",
"    ]. One child had a relapse that responded to a second course of treatment (personal communication).",
"   </p>",
"   <p>",
"    Based on the reports described above, we suggest using corticosteroids as the initial treatment for SC:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day as a single dose for two weeks and then tapered over two to three weeks. A repeat course may be required if an exacerbation occurs. Treatment with either valproic acid or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    is a reasonable alternative, although these drugs have less evidence for efficacy. We reserve the use of neuroleptics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     pimozide",
"    </a>",
"    for resistant or chronic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Antibiotic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic therapy of acute rheumatic fever and prophylaxis are discussed separately. Patients with SC should be treated with chronic antibiotics to prevent further streptococcal infections and the recurrence of rheumatic fever, to minimize the risk for rheumatic heart disease and recurrent SC. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment and prevention of acute rheumatic fever\", section on 'Secondary prevention'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     RECURRENT CHOREA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea recurs in 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/5\">",
"     5",
"    </a>",
"    ]. Most relapses occur within two to three years but can occur as late as ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/55\">",
"     55",
"    </a>",
"    ]. Repeated recurrences are less common. Patients not receiving continuous antibiotic prophylaxis are at increased risk and, in some reports, recurrence was seen only in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among patients receiving prophylaxis, recurrent chorea may not always correlate with repeat streptococcal infection [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. This issue was addressed in a study from Chile in which patients with SC received monthly prophylaxis with benzathine",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/56\">",
"     56",
"    </a>",
"    ]. Throat cultures were obtained just prior to injection each month, and serum antistreptolysin O and anti-DNAse B titers were measured at least every three months. During follow-up, there were 16 evaluable recurrences of \"pure\" chorea:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 12 recurrences, the serologic findings were suggestive (ie, modest elevations in antibody titers) or confirmatory of recent streptococcal infection.",
"     </li>",
"     <li>",
"      In four recurrences, the timing of serologic studies and onset of chorea appeared to exclude an immunologically significant streptococcal infection within the preceding six to nine months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors suggested that, in certain chorea-prone patients receiving antibiotic prophylaxis, SC recurs after streptococcal infection that is too weak or transient to be readily detectable or after stimuli other than streptococcal infection.",
"   </p>",
"   <p>",
"    In another study of 24 patients with SC, 11 episodes of recurrence occurred in ten patients (42 percent) during follow-up of as long as 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/55\">",
"     55",
"    </a>",
"    ]. Six of these episodes were probably associated with rheumatic fever (as indicated by acute rise in ASO titer in two, and discontinuation of, or poor adherence to, prophylaxis in four). In the remaining five patients, no clinical or laboratory evidence could link the recurrence with repeat streptococcal infection. The authors suggest that in some patients, recurrent chorea represents another primary abnormality (eg, autoimmunity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22007/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]) that predisposes to the development of movement disorders, or that recurrent chorea is the outcome of permanent subclinical damage to the basal ganglia after the initial SC episode. Additional studies comparing immunologic aspects of recurrent versus nonrecurrent cases may be helpful in elucidating the pathogenesis of recurrent chorea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H955875\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sydenham chorea (SC) is a movement disorder characterized by chorea, emotional lability, and hypotonia. It is one of the major clinical manifestations of acute rheumatic fever (ARF). It is seen in about one third of cases of ARF, most often in school-aged children. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms of SC usually begin one to eight months after the onset of ARF. The onset is typically insidious but may be abrupt. Neurologic symptoms include chorea (distal movements of the hands, rapid irregular jerking of the face and feet), muscle weakness (characterized by &ldquo;milkmaid&rsquo;s grip&rdquo;) and loss of fine motor control. The movements are continuous while the patient is awake but improve with sleep. The symptoms typically improve gradually, with a mean duration of 12 to 15 weeks (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Neurologic symptoms and signs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychiatric symptoms of SC include emotional changes (easy crying or inappropriate laughing), irritability, distractibility, and obsessive-compulsive symptoms. Obsessive-compulsive symptoms can precede, occur concomitant with, or occur after the onset of chorea. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Psychiatric symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At least 30 percent of individuals have clinical carditis in association with SC. However, a higher proportion of patients probably have carditis that is subclinical or resolved by the time that SC is diagnosed, as suggested by a high long-term risk for rheumatic heart disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Association with other manifestations of rheumatic fever'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      The diagnosis of SC is made clinically, based on characteristic neurological findings and a careful cardiac examination. If carditis is present, this confirms the diagnosis. The antistreptolysin O (ASLO) titer is of limited use in patients with SC, because titers generally peak before the onset of SC symptoms and children without rheumatic fever or SC often have low positive titers of ASLO. The antideoxyribonuclease (anti-DNAse) B titer is more useful for supporting the diagnosis of SC because it tends to remain elevated longer. Other causes of chorea should be excluded, including systemic lupus erythematosus, Huntington&rsquo;s disease, and Wilson&rsquo;s disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Most patients with SC recover fully without treatment, with symptoms lasting from a few weeks to one year or more. For those with significant impairment of motor function and the possibility of self injury, we suggest treatment with corticosteroids (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily for two weeks and then tapered over two to three weeks) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), because this tends to shorten the duration of the chorea symptoms. Treatment with either valproic acid or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      is a reasonable alternative, although these drugs have less evidence for efficacy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharmacologic therapy of chorea'",
"      </a>",
"      above.) &nbsp; &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      Up to 30 percent of individuals with SC experience a recurrence, usually within a few years of the initial episode. The risk is probably reduced, but not eliminated, by chronic treatment with prophylactic antibiotics. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Antibiotic therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Recurrent chorea'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/1\">",
"      Eshel G, Lahat E, Azizi E, et al. Chorea as a manifestation of rheumatic fever--a 30-year survey (1960-1990). Eur J Pediatr 1993; 152:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/2\">",
"      Veasy LG, Tani LY, Hill HR. Persistence of acute rheumatic fever in the intermountain area of the United States. J Pediatr 1994; 124:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/3\">",
"      Centers for Disease Control (CDC). Acute rheumatic fever--Utah. MMWR Morb Mortal Wkly Rep 1987; 36:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/4\">",
"      Stollerman GH. Rheumatic fever. Lancet 1997; 349:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/5\">",
"      Carapetis JR, Currie BJ. Rheumatic chorea in northern Australia: a clinical and epidemiological study. Arch Dis Child 1999; 80:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/6\">",
"      Benseler SM, Silverman ED. Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 2007; 16:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/7\">",
"      TARANTA A, STOLLERMAN GH. The relationship of Sydenham's chorea to infection with group A streptococci. Am J Med 1956; 20:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/8\">",
"      Husby G, van de Rijn I, Zabriskie JB, et al. Antibodies reacting with cytoplasm of subthalamic and caudate nuclei neurons in chorea and acute rheumatic fever. J Exp Med 1976; 144:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/9\">",
"      Kotby AA, El Badawy N, El Sokkary S, et al. Antineuronal antibodies in rheumatic chorea. Clin Diagn Lab Immunol 1998; 5:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/10\">",
"      Kirvan CA, Swedo SE, Heuser JS, Cunningham MW. Mimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 2003; 9:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/11\">",
"      Kirvan CA, Cox CJ, Swedo SE, Cunningham MW. Tubulin is a neuronal target of autoantibodies in Sydenham's chorea. J Immunol 2007; 178:7412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/12\">",
"      Weng NP, Yu-Lee LY, Sanz I, et al. Structure and specificities of anti-ganglioside autoantibodies associated with motor neuropathies. J Immunol 1992; 149:2518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/13\">",
"      Buchanon DN, Walker AE, Case TJ. The pathogenesis of chorea. J Pediatr 1942; 10:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/14\">",
"      Lange H, Th&ouml;rner G, Hopf A, Schr&ouml;der KF. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976; 28:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/15\">",
"      Giedd JN, Rapoport JL, Kruesi MJ, et al. Sydenham's chorea: magnetic resonance imaging of the basal ganglia. Neurology 1995; 45:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/16\">",
"      Traill Z, Pike M, Byrne J. Sydenham's chorea: a case showing reversible striatal abnormalities on CT and MRI. Dev Med Child Neurol 1995; 37:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/17\">",
"      Lee PH, Nam HS, Lee KY, et al. Serial brain SPECT images in a case of Sydenham chorea. Arch Neurol 1999; 56:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/18\">",
"      Aron AM. Sydenham's chorea: positron emission tomographic (PET) scan studies. J Child Neurol 2005; 20:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/19\">",
"      Zomorrodi A, Wald ER. Sydenham's chorea in western Pennsylvania. Pediatrics 2006; 117:e675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/20\">",
"      ARON AM, FREEMAN JM, CARTER S. THE NATURAL HISTORY OF SYDENHAM'S CHOREA. REVIEW OF THE LITERATURE AND LONG-TERM EVALUATION WITH EMPHASIS ON CARDIAC SEQUELAE. Am J Med 1965; 38:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/21\">",
"      Cardoso F, Vargas AP, Oliveira LD, et al. Persistent Sydenham's chorea. Mov Disord 1999; 14:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/22\">",
"      Kulkarni ML, Anees S. Sydenham's chorea. Indian Pediatr 1996; 33:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/23\">",
"      Gordon W. A Note on the Knee-Jerk in Chorea. Br Med J 1901; 1:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/24\">",
"      Ch'ien LT, Economides AN, Lemmi H. Sydenham's chorea and seizures. Clinical and electroencephalographic studies. Arch Neurol 1978; 35:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/25\">",
"      CHUN RW, SMITH NJ, FORSTER FM. Papilledema in Sydenham's chorea. Am J Dis Child 1961; 101:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/26\">",
"      COHEN MG. PSEUDOTUMOR CEREBRI FOLLOWING ACUTE RHEUMATIC FEVER. Del Med J 1963; 35:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/27\">",
"      Willetts GS. Obstruction of central retinal artery with Sydenham's chorea. Br Med J 1961; 5253:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/28\">",
"      FREEMAN JM, ARON AM, COLLARD JE, MACKAY MC. THE EMOTIONAL CORRELATES OF SYDENHAM'S CHOREA. Pediatrics 1965; 35:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/29\">",
"      Swedo SE, Leonard HL, Schapiro MB, et al. Sydenham's chorea: physical and psychological symptoms of St Vitus dance. Pediatrics 1993; 91:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/30\">",
"      Swedo SE, Rapoport JL, Cheslow DL, et al. High prevalence of obsessive-compulsive symptoms in patients with Sydenham's chorea. Am J Psychiatry 1989; 146:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/31\">",
"      Asbahr FR, Negr&atilde;o AB, Gentil V, et al. Obsessive-compulsive and related symptoms in children and adolescents with rheumatic fever with and without chorea: a prospective 6-month study. Am J Psychiatry 1998; 155:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/32\">",
"      Elevli M, Celebi A, Tombul T, G&ouml;kalp AS. Cardiac involvement in Sydenham's chorea: clinical and Doppler echocardiographic findings. Acta Paediatr 1999; 88:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/33\">",
"      Cardoso F, Seppi K, Mair KJ, et al. Seminar on choreas. Lancet Neurol 2006; 5:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/34\">",
"      Ayoub EM, Wannamaker LW. Streptococcal antibody titers in Sydenham's chorea. Pediatrics 1966; 38:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/35\">",
"      HARRIS TN, FRIEDMAN S, McLEAN DC. Determination of some streptococcal antibody titers and acute phase reactants in patients with chorea. Pediatrics 1958; 21:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/36\">",
"      Goldman S, Amrom D, Szliwowski HB, et al. Reversible striatal hypermetabolism in a case of Sydenham's chorea. Mov Disord 1993; 8:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/37\">",
"      HITCHENS RA. Recurrent attacks of acute rheumatism in school-children. Ann Rheum Dis 1958; 17:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/38\">",
"      LESSOF MH, BYWATERS EG. The duration of chorea. Br Med J 1956; 1:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/39\">",
"      Alvarez LA, Novak G. Valproic acid in the treatment of Sydenham chorea. Pediatr Neurol 1985; 1:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/40\">",
"      Dhanaraj M, Radhakrishnan AR, Srinivas K, Sayeed ZA. Sodium valproate in Sydenham's chorea. Neurology 1985; 35:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/41\">",
"      Oosterveer DM, Overweg-Plandsoen WC, Roos RA. Sydenham's chorea: a practical overview of the current literature. Pediatr Neurol 2010; 43:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/42\">",
"      Axley J. Rheumatic chorea controlled with haloperidol. J Pediatr 1972; 81:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/43\">",
"      al-Eissa A. Sydenham's chorea: a new look at an old disease. Br J Clin Pract 1993; 47:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/44\">",
"      Harries-Jones R, Gibson JG. Successful treatment of refractory Sydenham's chorea with pimozide. J Neurol Neurosurg Psychiatry 1985; 48:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/45\">",
"      Harel L, Zecharia A, Straussberg R, et al. Successful treatment of rheumatic chorea with carbamazepine. Pediatr Neurol 2000; 23:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/46\">",
"      Aranson N, Douglas HS, et al. Cortisone in Sydenham's chorea. JAMA 1951; 145:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/47\">",
"      Green LN. Corticosteroids in the treatment of Sydenham's chorea. Arch Neurol 1978; 35:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/48\">",
"      Barash J, Margalith D, Matitiau A. Corticosteroid treatment in patients with Sydenham's chorea. Pediatr Neurol 2005; 32:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/49\">",
"      Paz JA, Silva CA, Marques-Dias MJ. Randomized double-blind study with prednisone in Sydenham's chorea. Pediatr Neurol 2006; 34:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/50\">",
"      Thompson JA, Tani LY, Bale JF. Sydenham's chorea: the Utah experience (abstract). Ann Neurol 1999; 48:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/51\">",
"      Garvey MA, Snider LA, Leitman SF, et al. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. J Child Neurol 2005; 20:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/52\">",
"      van Immerzeel TD, van Gilst RM, Hartwig NG. Beneficial use of immunoglobulins in the treatment of Sydenham chorea. Eur J Pediatr 2010; 169:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/53\">",
"      Walker K, Brink A, Lawrenson J, et al. Treatment of sydenham chorea with intravenous immunoglobulin. J Child Neurol 2012; 27:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/54\">",
"      Golden AS, Haut SR, Mosh&eacute; SL. Nonepileptic uses of antiepileptic drugs in children and adolescents. Pediatr Neurol 2006; 34:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/55\">",
"      Korn-Lubetzki I, Brand A, Steiner I. Recurrence of Sydenham chorea: implications for pathogenesis. Arch Neurol 2004; 61:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/56\">",
"      Berrios X, Quesney F, Morales A, et al. Are all recurrences of \"pure\" Sydenham chorea true recurrences of acute rheumatic fever? J Pediatr 1985; 107:867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/57\">",
"      Church AJ, Dale RC, Cardoso F, et al. CSF and serum immune parameters in Sydenham's chorea: evidence of an autoimmune syndrome? J Neuroimmunol 2003; 136:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22007/abstract/58\">",
"      Church AJ, Cardoso F, Dale RC, et al. Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology 2002; 59:227.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6228 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-75239E8C8F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22007=[""].join("\n");
var outline_f21_31_22007=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H955875\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurologic symptoms and signs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychiatric symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Association with other manifestations of rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H956332\">",
"      Streptococcal antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H956339\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H956346\">",
"      Imaging and echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pharmacologic therapy of chorea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Antibiotic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      RECURRENT CHOREA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H955875\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/20/23879?source=related_link\">",
"      Clinical manifestations and diagnosis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/8/8327?source=related_link\">",
"      Epidemiology and pathogenesis of acute rheumatic fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8599?source=related_link\">",
"      Huntington disease: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/17/14617?source=related_link\">",
"      Natural history, screening, and management of rheumatic heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/2/44070?source=related_link\">",
"      Treatment and prevention of acute rheumatic fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_31_22008="Manifestations and causes of the sick sinus syndrome";
var content_f21_31_22008=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Manifestations and causes of the sick sinus syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22008/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22008/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22008/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22008/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22008/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22008/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/31/22008/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sick sinus syndrome (SSS) is characterized by dysfunction of the sinoatrial (SA) node that is often secondary to senescence of the SA node and surrounding atrial myocardium. The term \"sick sinus syndrome\" was first used in 1967 to describe the sluggish return of SA nodal activity in some patients following electrical electroversion and was later applied to a clinical syndrome characterized by chronic SA node dysfunction, a sluggish or absent SA nodal pacemaker after electrical electroversion, frequently depressed escape pacemakers,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atrioventricular (AV) nodal conduction disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. These abnormalities can result in profound sinus bradycardia, sinus pauses, sinus arrest, SA nodal exit block, and inappropriate responses to physiological demands during exercise or stress. SSS can also be accompanied by AV nodal conduction disturbances and by paroxysmal supraventricular tachycardia as part of the tachycardia-bradycardia syndrome. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Tachycardia-bradycardia syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The initial clues to the diagnosis of SSS are often clinical, as patients may present with symptoms of lightheadedness, presyncope, syncope, dyspnea on exertion, angina,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    palpitations. A routine electrocardiogram (ECG) may provide further information in such patients. However, the symptoms are nonspecific and the ECG changes may not be diagnostic, thereby necessitating either noninvasive or electrophysiologic studies to confirm the diagnosis. The diagnostic evaluation should also include a search for remediable causes of SA nodal depression, such as drugs (eg, beta blockers, calcium channel blockers,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    ), ischemia, and autonomic imbalance, prior to initiation of treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9064?source=see_link\">",
"     \"Diagnosis and evaluation of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of SSS is directed at symptoms. Control of symptomatic SSS usually involves the implantation of a pacemaker. Medications may be helpful in select cases, but are not as effective as permanent pacing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical manifestations, causes, and natural history of sick sinus syndrome will be reviewed here. The noninvasive and electrophysiologic evaluation of SSS, the treatment of SSS, and the appropriate timing of referral to a specialist are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9064?source=see_link\">",
"     \"Diagnosis and evaluation of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=see_link&amp;anchor=H9#H9\">",
"     \"Arrhythmia management for the primary care clinician\", section on 'Referral to a specialist'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with symptomatic SSS are primarily older, with frequent comorbid diseases and a high mortality rate. In three major trials of pacing in this disorder, the median or mean age was 73 to 76 years [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Although less common, SSS also occurs in younger adults and children. (See",
"    <a class=\"local\" href=\"#H6106301\">",
"     'Childhood and familial disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The sick sinus syndrome is defined by electrocardiographic criteria, since clinical signs and symptoms may be absent or quite varied. Importantly, sinus bradycardia may not always denote the presence of sick sinus syndrome. As an example, highly conditioned athletes often have a pronounced increase in vagal tone at rest with heart rates well below 60 beats per minute. Symptoms of lightheadedness, presyncope, or syncope are often the reason that the patient seeks medical attention. Other manifestations include increasing dyspnea on exertion, worsening angina, and, in patients with alternating bradycardia and tachycardia, palpitations and other symptoms associated with a rapid heart rate. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Tachycardia-bradycardia syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The characteristics of the sick sinus syndrome include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic, inappropriate, and often severe bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/1,3\">",
"       1,3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sinus pauses, arrest, and sinoatrial exit block with, and often without, appropriate atrial and junctional escape rhythms. The failure of escape pacemakers may lead to symptomatic bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/1,3\">",
"       1,3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=see_link\">",
"       \"Sinoatrial nodal pause, arrest, and exit block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alternating bradycardia and atrial tachyarrhythmias in over 50 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/1,4,7-11\">",
"       1,4,7-11",
"      </a>",
"      ]. AF is most common, but atrial flutter and paroxysmal supraventricular tachycardias may also occur.",
"     </li>",
"     <li>",
"      In the absence of drugs that slow AV conduction, AF with a slow ventricular response reflects associated dysfunction of the AV node. Spontaneous reversion or DC cardioversion will typically produce a slow and often unstable sinus rhythm [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/1-3\">",
"       1-3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Atrial arrhythmias seem to develop slowly over time [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/12,13\">",
"       12,13",
"      </a>",
"      ], possibly the result of a progressive pathological process that affects the SA node and the atrium [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The electrocardiographic manifestations may occur with or without symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An example of the ECG findings that may be seen is shown in the accompanying figure (",
"    <a class=\"graphic graphic_waveform graphicRef51193 \" href=\"UTD.htm?32/63/33783\">",
"     waveform 1",
"    </a>",
"    ). The patient initially has coarse atrial fibrillation with a slow ventricular response in the absence of drugs that slow AV nodal conduction. When atrial fibrillation spontaneously terminates, there is a delay before normal sinus activity resumes. The patient was symptomatic during these changes in rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of the sick sinus syndrome is made from the ECG and the history. There are, however, a variety of noninvasive and invasive tests that permit more complete evaluation of SA nodal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9064?source=see_link\">",
"     \"Diagnosis and evaluation of the sick sinus syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Tachycardia-bradycardia syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternating bradycardia and atrial tachyarrhythmias occur in over 50 percent of cases of SSS [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/1,4,7-11\">",
"     1,4,7-11",
"    </a>",
"    ]. AF is the most common atrial tachyarrhythmia and prolonged symptomatic pauses can occur after termination of AF that may result from tachycardia-mediated remodeling of the sinus node [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/15\">",
"     15",
"    </a>",
"    ]; such remodeling has also been demonstrated with atrial flutter [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/16\">",
"     16",
"    </a>",
"    ]. In at least some patients with tachy-brady syndrome associated with paroxysmal AF, radiofrequency ablation to prevent recurrence of AF can reverse sinus node remodeling as evidenced by a reduction in sinus node recovery time, increases in the mean and maximal heart rates, and no symptoms attributable to bradycardia or sinus pauses on ambulatory monitoring, thereby avoiding the need for pacemaker implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sinus node fibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of sick sinus syndrome is the replacement of sinus node tissue by fibrous tissue, which may be accompanied by degeneration and fibrosis of other parts of the conduction system including the AV node [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/10,14,18\">",
"     10,14,18",
"    </a>",
"    ]. The transitional junction between the sinus node and atrial tissue may also be involved, and there may be degeneration of nerve ganglia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Disease of the SA nodal artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SA nodal artery may be narrowed by atherosclerosis, inflammatory processes, or even emboli [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Some investigators suggest that coronary artery disease is a major cause [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/19\">",
"     19",
"    </a>",
"    ], while others have found the SA artery to be patent in the sick sinus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. As an example, approximately 5 percent of patients with myocardial infarction, usually inferior, show sinus node dysfunction that tends to be reversible [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. Furthermore, a correlative study of coronary artery anatomy and electrophysiologic testing found a correlation between the frequency of an abnormal intrinsic heart rate and the degree of narrowing of the SA nodal artery in patients with an acute myocardial infarction: the intrinsic heart rate was abnormal in almost all patients with more than a 75 percent narrowing, but only about 33 percent with less than 50 percent narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sick sinus syndrome is less often due to a variety of other disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltrative diseases &ndash; The SA node may be affected by infiltrative disease, such as amyloidosis, scleroderma [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/19\">",
"       19",
"      </a>",
"      ], hemochromatosis, and rarely tumor.",
"     </li>",
"     <li>",
"      Epicardial and pericardial disease &ndash; The SA node is located near the epicardium. As a result, diseases that involved the epicardium or pericardium (such as pericarditis and tumors) may affect the SA nodal function [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/18,19,22,29,30\">",
"       18,19,22,29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory diseases &ndash; Rheumatic fever, pericarditis, diphtheria, Chagas disease, Lyme disease, and other disorders may depress SA nodal function.",
"     </li>",
"     <li>",
"      Primary SA node dysfunction &ndash; The sinus node disease may be intrinsic, induced by autonomic abnormalities, or both [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/31-34\">",
"       31-34",
"      </a>",
"      ] (see below).",
"     </li>",
"     <li>",
"      Drugs and toxins &ndash; A number of drugs and toxins can depress sinus node function. Drugs associated with sinus node dysfunction include parasympathomimetic agents, sympatholytic drugs (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"       reserpine",
"      </a>",
"      , guanethidine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , beta blockers),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      , digitalis, calcium channel blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      and other antiarrhythmic drugs, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/35-42\">",
"       35-42",
"      </a>",
"      ]. In addition, poisoning by grayanotoxin, produced by some plants (eg,",
"      <em>",
"       Rhododendron sp.",
"      </em>",
"      ) and found in certain varieties of honey, has been associated with depressed sinus node function [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trauma &ndash; Cardiac trauma during surgery may affect either the SA node directly or its blood supply.",
"     </li>",
"     <li>",
"      Miscellaneous &ndash; Other disorders that can induce the sick sinus syndrome include hypothyroidism, hypothermia, hypoxia, and muscular dystrophies. Some infections (eg, leptospirosis, trichinosis, and Salmonella typhosa) are associated with relative sinus bradycardia, but permanent sick sinus syndrome has not followed these [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/44-47\">",
"       44-47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Intrinsic versus extrinsic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus node dysfunction is due with roughly equal frequency to intrinsic disease of the sinus node and to extrinsic autonomic influences [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. The extrinsic type is more commonly seen in younger patients, often without evident organic heart disease. Both increased vagal tone and perhaps a deficiency in atrial cholinesterase, which leads to an abundance of acetylcholine for release in tissues, may be important in this setting.",
"   </p>",
"   <p>",
"    Another potential cause, particularly in patients with primary or Chagasic sinus node dysfunction, is circulating anti-M2-cholinergic receptor antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/48\">",
"     48",
"    </a>",
"    ]. These antibodies stimulate cholinergic receptors, decreasing chronotropism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6106301\">",
"    <span class=\"h2\">",
"     Childhood and familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sick sinus syndrome in children is seen with congenital and acquired heart disease, particularly after corrective cardiac surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. In a series of 30 children and young adults, 22 had significant cardiac disease, and sinus node dysfunction developed after cardiac surgery in 13 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/49\">",
"     49",
"    </a>",
"    ]. The causes of sinus node dysfunction were inappropriate sinus bradycardia, sinus arrest, and sinoatrial exit block.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6106341\">",
"    <span class=\"h3\">",
"     SCN5A mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial sick sinus syndrome is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/53-59\">",
"     53-59",
"    </a>",
"    ]. Mutations in the cardiac sodium channel gene SCN5A may be responsible for some familial cases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 10 children from seven families with familial sick sinus syndrome, genomic DNA encoding the alpha subunit of the cardiac sodium channel was screened for mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/53\">",
"       53",
"      </a>",
"      ]. Compound heterozygous nucleotide changes were identified in five children from three families (but in none of over 75 control subjects).",
"     </li>",
"     <li>",
"      In a series of 38 patients with clinical evidence of Brugada syndrome, four had SCN5A mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/56\">",
"       56",
"      </a>",
"      ]. Three of these patients had SSS with multiple affected family members.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Mutations in SCN5A are not pathognomonic for sinus node disease. In fact, different SCN5A mutations are associated with other cardiac abnormalities including Brugada syndrome, congenital long QT syndrome type 3, familial AV block, and familial dilated cardiomyopathy with conduction defects and susceptibility to atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=see_link\">",
"     \"Genetics of congenital and acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=see_link\">",
"     \"Etiology of atrioventricular block\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=see_link\">",
"     \"Genetics of dilated cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6106348\">",
"    <span class=\"h3\">",
"     HCN4 mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HCN4 gene codes for the alpha subunit of a hyperpolarization-activated cyclic nucleotide-gated cation channel, thought to contribute to the pacemaker current in the sinus node.",
"   </p>",
"   <p>",
"    Mutations in HCN4 can produce both symptomatic and asymptomatic sinus node dysfunction, as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two patients with idiopathic sinus node dysfunction have been reported with a heterozygous mutation of the HCN4 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/57,58\">",
"       57,58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A mutation of the HCN4 gene was identified in 15 members of a single family with asymptomatic sinus bradycardia [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/59\">",
"       59",
"      </a>",
"      ]. Compared to 12 unaffected family members, those with the HCN4 mutation had a lower resting heart rate (52 versus 73",
"      <span class=\"nowrap\">",
"       beats/min).",
"      </span>",
"     </li>",
"     <li>",
"      Eight members of a family with asymptomatic sinus bradycardia shared a missense mutation in the HCN4 gene [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although two of these families had asymptomatic bradycardia, HCN4 is one of a family of pacemaker ion channel genes, and these findings provide targets for future investigations in this area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Rhythm",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a tendency for the rhythm disturbances associated with sick sinus syndrome to evolve over time:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are variable, and often long, periods of normal sinus node function [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/61\">",
"       61",
"      </a>",
"      ]. Nevertheless, once present, sinus node dysfunction eventually progresses in most patients. As an example, one study evaluated 52 patients with sick sinus syndrome who presented with sinus bradycardia associated with SA block or SA arrest; it took an average of 13 years (range 7 to 29 years) for progression to complete SA arrest [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Intrinsic sinus node function tends to deteriorate with age [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/62\">",
"       62",
"      </a>",
"      ]. Although not definitively established, patients with intrinsic (versus extrinsic) sick sinus syndrome appear to be more likely to have progressive SA nodal dysfunction with failure of lower pacemakers; they are therefore more likely to require permanent electrical pacemakers.",
"     </li>",
"     <li>",
"      Atrial arrhythmias and conduction disturbances become more common over time [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/12,13\">",
"       12,13",
"      </a>",
"      ], possibly the result of a progressive pathological process that affects the SA node and the atrium [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/14\">",
"       14",
"      </a>",
"      ]. As an example, 213 patients with a history of",
"      <strong>",
"       symptomatic",
"      </strong>",
"      sick sinus syndrome were treated with atrial pacing for a median follow-up period of five years [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/63\">",
"       63",
"      </a>",
"      ]. Although the atrial rate was controlled by pacing, 7 percent developed atrial fibrillation (particularly patients over age 70) and 8.5 percent developed high-grade AV block. The latter complication much occurred more often in patients with complete bundle branch or fascicular block (35 percent) as compared to those without infranodal conduction disturbances (6 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cardiovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sick sinus syndrome are at increased risk of cardiovascular events. One prospective study evaluated 35 untreated patients aged &ge;45 years with sick sinus syndrome manifested by a mean sinus rate at rest &le;50",
"    <span class=\"nowrap\">",
"     beats/min",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intermittent SA block, and associated symptoms. After a mean follow-up of 17 months the following findings were observed (",
"    <a class=\"graphic graphic_figure graphicRef54588 \" href=\"UTD.htm?15/50/16173\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cardiovascular event requiring treatment occurred in 57 percent of patients and included syncope (23 percent), overt heart failure (17 percent), chronic AF (11 percent), or poorly tolerated atrial arrhythmias (6 percent).",
"     </li>",
"     <li>",
"      The actuarial rates for the occurrence of all events at one, two, and four years were 35, 49, and 63 percent, respectively; rates for syncope were 16, 31, and 31 percent, respectively.",
"     </li>",
"     <li>",
"      With multivariate analysis, independent predictors of a cardiovascular event were age, left ventricular end-diastolic diameter, and left ventricular ejection fraction. Independent predictors of syncope were a history of syncope and corrected sinus node recovery time &ge;800 ms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar to patients with AF, patients with sick sinus syndrome, particularly those with alternating bradycardia and tachycardia, are at an increased risk for thromboembolic events even after pacemaker implantation. In a study of 225 patients randomized to single chamber atrial or ventricular pacing, the annual risk of thromboembolism was 5.8 and 3 percent in those with a",
"    <span class=\"nowrap\">",
"     bradycardia/tachycardia",
"    </span>",
"    who had an atrial or ventricular pacemaker, respectively; the risk in those without a",
"    <span class=\"nowrap\">",
"     bradycardia/tachycardia",
"    </span>",
"    was 3.2 and 1.5 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible contributor to cardiovascular events after pacemaker implantation is asymptomatic episodes of AF. Current pacemakers can record and store episodes of spontaneous atrial tachyarrhythmias that are thought to represent nonsustained AF.",
"   </p>",
"   <p>",
"    The significance of these atrial high-rate events (AHREs) was evaluated in a secondary analysis from the MOST trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/66\">",
"     66",
"    </a>",
"    ]. Among a subset of 312 patients who were enrolled in an atrial diagnostics ancillary study, 160 (51 percent) had at least one AHRE lasting more than five minutes by one year; these patients were significantly more likely to have a history of prior supraventricular arrhythmia. The median time to first AHRE was 100 days.",
"   </p>",
"   <p>",
"    The presence of any AHRE was an independent predictor of death (17.5 versus 10.5 percent in the no AHRE group, hazard ratio [HR] 2.48), death or nonfatal stroke (20.6 versus 10.5 percent, HR 2.79), and AF (39 versus 2 percent, HR 5.93). Pacing mode (DDDR or VVIR) had no effect on AHREs, and symptoms had a specificity of only 38 percent. A similar increase in risk with pacemaker-detected AHREs has been noted by others [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The mortality of patients with sick sinus syndrome is significant and not always due to cardiac causes. This was demonstrated in an analysis from the MOST trial [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/68\">",
"     68",
"    </a>",
"    ]. Of 2010 patients (median age 74 years) in the study, 404 (20 percent) had died at a median of 33 months of follow-up. The cause of death was cardiac in 35 percent, noncardiac in 49 percent, and unknown in 16 percent. Independent predictors of death included age, male sex, weight, prior myocardial infarction, cardiomyopathy, and measures of functional status and comorbidity. In addition, as noted in the previous section, patients with a pacemaker-detected atrial high-rate events lasting more than five minutes are at increased risk for mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22008/abstract/66\">",
"     66",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=see_link\">",
"     \"Treatment of the sick sinus syndrome\"",
"    </a>",
"    .) While pacemakers may reduce morbidity, they have not been shown to reduce mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=see_link\">",
"       \"Patient information: Sick sinus syndrome (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=see_link\">",
"       \"Patient information: Bradycardia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6105633\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sick sinus syndrome (SSS) is defined by electrocardiographic criteria since clinical signs and symptoms may only manifest occasionally and may be quite varied. The electrocardiographic characteristics of the sick sinus syndrome include (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical characteristics'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Chronic, inappropriate, and often severe bradycardia.",
"     </li>",
"     <li>",
"      Sinus pauses, arrest, and sinoatrial exit block with, and often without, appropriate atrial and junctional escape rhythms.",
"     </li>",
"     <li>",
"      Alternating bradycardia and atrial tachyarrhythmias in over 50 percent of cases, with atrial fibrillation (AF) being the most common atrial tachyarrhythmia.",
"     </li>",
"     <li>",
"      In the absence of drugs that slow atrioventricular (AV) conduction, AF with a slow ventricular response reflects associated dysfunction of the AV node.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Symptoms of lightheadedness, presyncope, or syncope are often the reason that the patient seeks medical attention. Other manifestations include increasing dyspnea on exertion, worsening angina, and, in patients with alternating bradycardia and tachycardia, palpitations and other symptoms associated with a rapid heart rate. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common cause of SSS is the replacement of sinus node tissue by fibrous tissue, which may be accompanied by degeneration and fibrosis of other parts of the conduction system including the AV node. In addition, blood supply to the SA may be compromised (eg, by atherosclerosis, an inflammatory processes, or embolic disease) or the SA node may be involved in other systemic illnesses (eg, infiltrative disease, malignancy, Lyme disease). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of drugs can depress sinus node function, including parasympathomimetic agents, sympatholytic drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"       reserpine",
"      </a>",
"      , guanethidine,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , beta blockers),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      , digitalis, calcium channel blockers,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      and other antiarrhythmic drugs. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While SSS is more often seen in adults, it has been described in children with congenital and acquired heart disease, particularly after corrective cardiac surgery. In addition, rare familial cases of SSS associated with specific gene mutations have been reported. (See",
"      <a class=\"local\" href=\"#H6106301\">",
"       'Childhood and familial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are variable and often long periods of normal sinus node function. However, sinus node dysfunction eventually progresses in most patients, with the majority ultimately requiring implantation of a permanent pacemaker. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/1\">",
"      Ferrer MI. The sick sinus syndrome in atrial disease. JAMA 1968; 206:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/2\">",
"      Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J 1967; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     Ferrer MI. The Sick Sinus Syndrome, Futura Press, New York 1974.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/4\">",
"      Lamas GA, Lee KL, Sweeney MO, et al. Ventricular pacing or dual-chamber pacing for sinus-node dysfunction. N Engl J Med 2002; 346:1854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/5\">",
"      Connolly SJ, Kerr CR, Gent M, et al. Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. N Engl J Med 2000; 342:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/6\">",
"      Andersen HR, Thuesen L, Bagger JP, et al. Prospective randomised trial of atrial versus ventricular pacing in sick-sinus syndrome. Lancet 1994; 344:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/7\">",
"      SHORT DS. The syndrome of alternating bradycardia and tachycardia. Br Heart J 1954; 16:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/8\">",
"      BIRCHFIELD RI, MENEFEE EE, BRYANT GD. Disease of the sinoatrial node associated with bradycardia, asystole, syncope, and paroxysmal atrial fibrillation. Circulation 1957; 16:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/9\">",
"      Rubenstein JJ, Schulman CL, Yurchak PM, DeSanctis RW. Clinical spectrum of the sick sinus syndrome. Circulation 1972; 46:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/10\">",
"      Kaplan BM, Langendorf R, Lev M, Pick A. Tachycardia-bradycardia syndrome (so-called \"sick sinus syndrome\"). Pathology, mechanisms and treatment. Am J Cardiol 1973; 31:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/11\">",
"      Gomes JA, Kang PS, Matheson M, et al. Coexistence of sick sinus rhythm and atrial flutter-fibrillation. Circulation 1981; 63:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/12\">",
"      Ferrer MI. The etiology and natural history of sinus node disorders. Arch Intern Med 1982; 142:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/13\">",
"      Simonsen E, Nielsen JS, Nielsen BL. Sinus node dysfunction in 128 patients. A retrospective study with follow-up. Acta Med Scand 1980; 208:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/14\">",
"      Thery C, Gosselin B, Lekieffre J, Warembourg H. Pathology of sinoatrial node. Correlations with electrocardiographic findings in 111 patients. Am Heart J 1977; 93:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/15\">",
"      Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation 1996; 94:2953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/16\">",
"      Sparks PB, Jayaprakash S, Vohra JK, Kalman JM. Electrical remodeling of the atria associated with paroxysmal and chronic atrial flutter. Circulation 2000; 102:1807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/17\">",
"      Hocini M, Sanders P, Deisenhofer I, et al. Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses. Circulation 2003; 108:1172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/18\">",
"      HUDSON RE. The human pacemaker and its pathology. Br Heart J 1960; 22:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/19\">",
"      James TN. The sinus node. Am J Cardiol 1977; 40:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/20\">",
"      James TN, Birk RE. Pathology of the cardiac conduction system in polyarteritis nodosa. Arch Intern Med 1966; 117:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/21\">",
"      JAMES TN, RUPE CE, MONTO RW. PATHOLOGY OF THE CARDIAC CONDUCTION SYSTEM IN SYSTEMIC LUPUS ERYTHEMATOSUS. Ann Intern Med 1965; 63:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/22\">",
"      Demoulin JC, Kulbertus HE. Histopathological correlates of sinoatrial disease. Br Heart J 1978; 40:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/23\">",
"      Engel TR, Meister SG, Feitosa GS, et al. Appraisal of sinus node artery disease. Circulation 1975; 52:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/24\">",
"      Evans R, Shaw DB. Pathological studies in sinoatrial disorder (sick sinus syndrome). Br Heart J 1977; 39:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/25\">",
"      Hatle L, Bathen J, Rokseth R. Sinoatrial disease in acute myocardial infarction. Long-term prognosis. Br Heart J 1976; 38:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/26\">",
"      Rokseth R, Hatle L. Sinus arrest in acute myocardial infarction. Br Heart J 1971; 33:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/27\">",
"      Simonsen E, Nielsen BL, Nielsen JS. Sinus node dysfunction in acute myocardial infarction. Acta Med Scand 1980; 208:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/28\">",
"      Alboni P, Baggioni GF, Scarf&ograve; S, et al. Role of sinus node artery disease in sick sinus syndrome in inferior wall acute myocardial infarction. Am J Cardiol 1991; 67:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/29\">",
"      JAMES TN. Pericarditis and the sinus node. Arch Intern Med 1962; 110:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/30\">",
"      Metzger AL, Goldbarg AN, Hunter RL. Sick sinus node syndrome as the presenting manifestation of reticulum cell sarcoma. Chest 1971; 60:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/31\">",
"      Jordan JL, Yamaguchi I, Mandel WJ. Studies on the mechanism of sinus node dysfunction in the sick sinus syndrome. Circulation 1978; 57:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/32\">",
"      Kang PS, Gomes JA, Kelen G, El-Sherif N. Role of autonomic regulatory mechanism in sinoatrial conduction and sinus node automaticity in sick sinus syndrome. Circulation 1981; 64:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/33\">",
"      Kang PS, Gomes JA, El-Sherif N. Differential effects of functional autonomic blockade on the variables of sinus nodal automaticity in sick sinus syndrome. Am J Cardiol 1982; 49:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/34\">",
"      Desai JM, Scheinman MM, Strauss HC, et al. Electrophysiologic effects on combined autonomic blockade in patients with sinus node disease. Circulation 1981; 63:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/35\">",
"      Margolis JR, Strauss HC, Miller HC, et al. Digitalis and the sick sinus syndrome. Clinical and electrophysiologic documentation of severe toxic effect on sinus node function. Circulation 1975; 52:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/36\">",
"      Strauss HC, Gilbert M, Svenson RH, et al. Electrophysiologic effects of propranolol on sinus node function in patients with sinus node dysfunction. Circulation 1976; 54:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/37\">",
"      Breithardt G, Seipel L, Wiebringhaus E, Loogen F. Effects of verapamil on sinus node function in man. Eur J Cardiol 1978; 8:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/38\">",
"      Vera Z, Awan NA, Mason DT. Assessment of oral quinidine effects on sinus node function in sick sinus syndrome patients. Am Heart J 1982; 103:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/39\">",
"      LaBarre A, Strauss HC, Scheinman MM, et al. Electrophysiologic effects of disopyramide phosphate on sinus node function in patients with sinus node dysfunction. Circulation 1979; 59:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/40\">",
"      Kim HG, Friedman HS. Procainamide-induced sinus node dysfunction in patients with chronic renal failure. Chest 1979; 76:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/41\">",
"      Weintraub M, Hes JP, Rotmensch HH, et al. Extreme sinus bradycardia associated with lithium therapy. Isr J Med Sci 1983; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/42\">",
"      Thormann J, Neuss H, Schlepper M, Mitrovic V. Effects of clonidine on sinus node function in man. Chest 1981; 80:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/43\">",
"      Lennerz C, Jilek C, Semmler V, et al. Sinus arrest from mad honey disease. Ann Intern Med 2012; 157:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/44\">",
"      Puljiz I, Beus A, Kuzman I, Seiwerth S. Electrocardiographic changes and myocarditis in trichinellosis: a retrospective study of 154 patients. Ann Trop Med Parasitol 2005; 99:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/45\">",
"      Assimakopoulos SF, Michalopoulou S, Papakonstantinou C, et al. A case of severe sinus bradycardia complicating anicteric leptospirosis. Am J Med Sci 2007; 333:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/46\">",
"      Cunha BA, Thermidor M, Mohan S, et al. Fever of unknown origin: subacute thyroiditis versus typhoid fever. Heart Lung 2005; 34:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/47\">",
"      Cunha BA. The diagnostic significance of relative bradycardia in infectious disease. Clin Microbiol Infect 2000; 6:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/48\">",
"      Chiale PA, Ferrari I, Mahler E, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001; 103:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/49\">",
"      Yabek SM, Jarmakani JM. Sinus node dysfunction in children, adolescents, and young adults. Pediatrics 1978; 61:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/50\">",
"      Hayes CJ, Gersony WM. Arrhythmias after the Mustard operation for transposition of the great arteries: a long-term study. J Am Coll Cardiol 1986; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/51\">",
"      Beder SD, Gillette PC, Garson A Jr, et al. Symptomatic sick sinus syndrome in children and adolescents as the only manifestation of cardiac abnormality or associated with unoperated congenital heart disease. Am J Cardiol 1983; 51:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/52\">",
"      Greenwood RD, Rosenthal A, Sloss LJ, et al. Sick sinus syndrome after surgery for congenital heart disease. Circulation 1975; 52:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/53\">",
"      Benson DW, Wang DW, Dyment M, et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003; 112:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/54\">",
"      Caralis DG, Varghese PJ. Familial sinoatrial node dysfunction. Increased vagal tone a possible aetiology. Br Heart J 1976; 38:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/55\">",
"      Bharati S, Surawicz B, Vidaillet HJ Jr, Lev M. Familial congenital sinus rhythm anomalies: clinical and pathological correlations. Pacing Clin Electrophysiol 1992; 15:1720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/56\">",
"      Makiyama T, Akao M, Tsuji K, et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005; 46:2100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/57\">",
"      Schulze-Bahr E, Neu A, Friederich P, et al. Pacemaker channel dysfunction in a patient with sinus node disease. J Clin Invest 2003; 111:1537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/58\">",
"      Ueda K, Nakamura K, Hayashi T, et al. Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia. J Biol Chem 2004; 279:27194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/59\">",
"      Milanesi R, Baruscotti M, Gnecchi-Ruscone T, DiFrancesco D. Familial sinus bradycardia associated with a mutation in the cardiac pacemaker channel. N Engl J Med 2006; 354:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/60\">",
"      Nof E, Luria D, Brass D, et al. Point mutation in the HCN4 cardiac ion channel pore affecting synthesis, trafficking, and functional expression is associated with familial asymptomatic sinus bradycardia. Circulation 2007; 116:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/61\">",
"      Lien WP, Lee YS, Chang FZ, et al. The sick sinus syndrome: natural history of dysfunction of the sinoatrial node. Chest 1977; 72:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/62\">",
"      Kuga K, Yamaguchi I, Sugishita Y, Ito I. Assessment by autonomic blockade of age-related changes of the sinus node function and autonomic regulation in sick sinus syndrome. Am J Cardiol 1988; 61:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/63\">",
"      Brandt J, Anderson H, F&aring;hraeus T, Sch&uuml;ller H. Natural history of sinus node disease treated with atrial pacing in 213 patients: implications for selection of stimulation mode. J Am Coll Cardiol 1992; 20:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/64\">",
"      Menozzi C, Brignole M, Alboni P, et al. The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome. Am J Cardiol 1998; 82:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/65\">",
"      Andersen HR, Nielsen JC, Thomsen PE, et al. Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings. Heart 1999; 81:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/66\">",
"      Glotzer TV, Hellkamp AS, Zimmerman J, et al. Atrial high rate episodes detected by pacemaker diagnostics predict death and stroke: report of the Atrial Diagnostics Ancillary Study of the MOde Selection Trial (MOST). Circulation 2003; 107:1614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/67\">",
"      Tse HF, Lau CP. Prevalence and clinical implications of atrial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome. Heart 2005; 91:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22008/abstract/68\">",
"      Flaker G, Greenspon A, Tardiff B, et al. Death in patients with permanent pacemakers for sick sinus syndrome. Am Heart J 2003; 146:887.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 940 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-90821EDB07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22008=[""].join("\n");
var outline_f21_31_22008=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6105633\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Tachycardia-bradycardia syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sinus node fibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Disease of the SA nodal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Intrinsic versus extrinsic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6106301\">",
"      Childhood and familial disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6106341\">",
"      - SCN5A mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6106348\">",
"      - HCN4 mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Rhythm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6105633\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/940\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/940|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/50/16173\" title=\"figure 1\">",
"      Outcome sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/940|Waveform\">",
"      <a href=\"#\" title=\"WAVEFORMS\">",
"       WAVEFORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_waveform\" href=\"UTD.htm?32/63/33783\" title=\"waveform 1\">",
"      ECG sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/28/33223?source=related_link\">",
"      Arrhythmia management for the primary care clinician",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/54/9064?source=related_link\">",
"      Diagnosis and evaluation of the sick sinus syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/16/32007?source=related_link\">",
"      Etiology of atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28681?source=related_link\">",
"      Genetics of congenital and acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/41/39576?source=related_link\">",
"      Genetics of dilated cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/46/8931?source=related_link\">",
"      Patient information: Bradycardia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/40/19075?source=related_link\">",
"      Patient information: Sick sinus syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38756?source=related_link\">",
"      Sinoatrial nodal pause, arrest, and exit block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/44/37576?source=related_link\">",
"      Treatment of the sick sinus syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_31_22009="Pathologic characteristics of melanoma";
var content_f21_31_22009=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathologic characteristics of melanoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22009/contributors\">",
"     April W Armstrong, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Vincent Liu, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Martin C Mihm, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Hensin Tsao, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?21/31/22009/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?21/31/22009/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanoma is the most serious form of skin cancer and the sixth most common cancer in North America [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here we will review the pathologic features of cutaneous melanoma, including its growth phases, major histologic subtypes, and rare variants. Other aspects of melanoma, including the pathologic approach to evaluation of locoregional lymph nodes are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=see_link\">",
"       \"Risk factors for the development of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=see_link\">",
"       \"Inherited susceptibility to melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=see_link\">",
"       \"Screening and early detection of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=see_link\">",
"       \"Skin examination and clinical features of melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"       \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1206?source=see_link\">",
"       \"Pathologic evaluation of regional lymph nodes in melanoma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26207195\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for patients with melanoma is primarily determined by the thickness of the primary tumor, ulceration, mitotic rate, and presence and extent of metastatic disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to other skin cancers (eg, squamous and basal cell carcinomas), melanomas are aggressive neoplasms that may spread in an unpredictable manner to involve virtually any organ of the body. Early diagnosis and treatment is the key to minimizing morbidity and mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=see_link\">",
"     \"Epidemiology and clinical features of basal cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=see_link\">",
"     \"Epidemiology and risk factors for cutaneous squamous cell carcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"     \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnostic and prognostic information provided by pathologic review of the surgical specimen influences the selection of treatment for patients with melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/2\">",
"     2",
"    </a>",
"    ]. However, accurate pathologic diagnosis can be challenging, even to the most experienced pathologist, due to variability in cytomorphology and architecture, and the similarity of some melanomas to benign nevomelanocytic lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GROWTH PHASES OF MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;During embryogenesis, the neural crest-derived melanocytes migrate into the epidermis and hair follicles to reside in the basal layer of the epidermis. These melanocytes, which are spaced at approximately every tenth cell along the basal layer, possess dendritic processes that transfer melanosomes to neighboring keratinocytes and hair matrices.",
"   </p>",
"   <p>",
"    Nevi (both congenital and acquired) are composed of nevus cells, which are melanocytes that have lost their dendritic processes and typically proliferate clonally to form nests of cells. The more common acquired nevus begins as a flat lesion (junctional nevus) and over time progresses to an elevated lesion (compound nevus). Historically, the concept of abtropfung, or \"dropping off\" of nevus cells into the dermis, has been used to explain progression from a junctional to a compound nevus. However, this concept has been challenged. The alternative melanocyte differentiation pathway postulates that the upward migration of melanocytes into the epidermis forms the basis of nevus formation.",
"   </p>",
"   <p>",
"    Most malignant melanomas arise as superficial indolent tumors that are confined to the epidermis, where they remain for several years. During this stage, known as the horizontal or \"radial\" growth phase, the melanoma is almost always curable by surgical excision alone. At some point, probably in response to the stepwise accumulation of genetic abnormalities, the melanoma is transformed into an expansile nodule which extends beyond the biologic boundary of the basement membrane and invades the dermis. Although the molecular changes that accompany melanocytic tumor progression are not yet elucidated, the technique of comparative genomic hybridization has yielded important insights into the progression of these neoplasms [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/3\">",
"     3",
"    </a>",
"    ]. Gene amplifications at specific loci, especially those encoding proteins involved in cell-cycle progression, have been associated with the acquisition of metastatic potential early in the progression of some melanomas, such as acral melanomas. By contrast, these gene amplifications are found less frequently in other histologic subtypes of melanomas, and if present, they arise in later stages of tumor progression [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some superficially invasive malignant melanomas (termed \"microinvasive radial growth phase\" melanomas) remain highly curable with surgery alone, but those that infiltrate deep into the dermis are considered to be in a \"vertical\" growth phase, and have metastatic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/5\">",
"     5",
"    </a>",
"    ]. Biologically, vertical growth phase melanomas have different cell surface antigen expression, cytogenetic profiles, and growth characteristics that enhance their metastatic propensity [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radial growth phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radial growth phase melanomas are thin, primarily confined to the epidermis (",
"    <a class=\"graphic graphic_picture graphicRef51802 \" href=\"UTD.htm?41/2/42020\">",
"     picture 1",
"    </a>",
"    ), and behave in an indolent fashion. These melanomas are represented by two histopathologic patterns&mdash;in situ melanomas and microinvasive melanomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     In situ melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant melanoma in situ (MMIS) is a form of radial growth phase melanoma in which the proliferation of malignant melanocytes is restricted to the epidermis. Of the four major subtypes of melanoma, an in situ form exists for superficial spreading, acral lentiginous, and lentigo maligna melanomas, but not nodular melanomas. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Major subtypes of invasive melanoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the superficial spreading variant of MMIS, the malignant melanocytes extend away from their normal position along the basal layer throughout the epidermis, and even into the stratum corneum, a phenomenon termed \"pagetoid spread\" (",
"    <a class=\"graphic graphic_picture graphicRef61083 \" href=\"UTD.htm?23/61/24534\">",
"     picture 2",
"    </a>",
"    ). Acral lentiginous MMIS is characterized by uniformly atypical dendritic melanocytes that are aligned in a contiguous array along the dermal-epidermal junction.",
"   </p>",
"   <p>",
"    There is confusion in the literature and a lack of consensus regarding the definition of MMIS of the lentigo maligna type. We define MMIS-lentigo maligna type as an in situ melanoma that is characterized by continuous lentiginous proliferation of atypical cells with pagetoid spread that involves the full thickness of the epidermis (",
"    <a class=\"graphic graphic_picture graphicRef53790 \" href=\"UTD.htm?5/57/6037\">",
"     picture 3",
"    </a>",
"    ). In contrast, the term lentigo maligna refers to a premalignant lesion that is characterized by less continuous lentiginous proliferation, lower cellularity, and less than full thickness pagetoid spread [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/10\">",
"     10",
"    </a>",
"    ]. Once the tumor becomes invasive, the lesion is considered lentigo maligna melanoma. Thus, lentigo maligna, MMIS-lentigo maligna type, and lentigo maligna melanoma should be considered as stages along a spectrum of malignant progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Microinvasive radial growth phase melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to epidermal involvement, microinvasive melanomas are characterized by microscopic papillary dermal extension, and they tend to behave in an indolent fashion (",
"    <a class=\"graphic graphic_picture graphicRef71855 \" href=\"UTD.htm?19/6/19557\">",
"     picture 4",
"    </a>",
"    ). By definition, the largest dermal \"nest\" can be no larger than the largest epidermal nest, and dermal mitoses are not allowed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast to more invasive melanomas that involve the dermis, the morphology of the dermal nevomelanocytes is similar to that of the epidermal component. Frequently, a predominantly lymphocytic inflammatory infiltrate is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Vertical growth phase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most vertical growth phase melanomas are clearly invasive, extending deeply into the dermis (",
"    <a class=\"graphic graphic_picture graphicRef54748 graphicRef75460 \" href=\"UTD.htm?29/29/30170\">",
"     picture 5A-B",
"    </a>",
"    ). Included in the term \"vertical growth phase melanoma\" are lesions that are associated with an expansile nodule filling the papillary dermis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    invasion of reticular dermis or fat. These features correspond to the histologic level of invasion (Clark level) III, IV, and V [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/5\">",
"     5",
"    </a>",
"    ]. Some Clark level II lesions can qualify as vertical growth phase lesions if a dermal nest is larger than the largest epidermal nest, or there is a mitosis in the dermis.",
"   </p>",
"   <p>",
"    Once a melanoma enters a vertical growth phase, it possesses the potential for metastasis. By definition, a vertical growth phase melanoma has at least one dermal mitosis or one dermal nest larger than the largest epidermal nest. These features represent the earliest histologic evidence of progression from a nonmetastatic to a potentially metastatic lesion.",
"   </p>",
"   <p>",
"    Vertical growth phase melanomas can arise de novo or from a radial growth phase melanoma. It may take decades for some melanomas to reach vertical growth phase, while others develop an early vertical growth phase. Nodular melanomas have no identifiable radial growth phase, and enter the vertical growth phase almost from their inception. The probability of metastases with invasive, vertical growth phase melanoma may be predicted by measuring in millimeters the depth of invasion of the vertical growth phase nodule below the granular cell layer of the overlying epidermis, as described originally by Breslow [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H2#H2\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Prognostic factors affecting staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     MAJOR SUBTYPES OF INVASIVE MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Melanomas are characterized by significant morphologic diversity, and four distinct histologic patterns are described [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/13\">",
"     13",
"    </a>",
"    ]. In descending order of frequency, these are superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, and acral lentiginous melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/14\">",
"     14",
"    </a>",
"    ]. Although histologic subtype does not directly correlate with clinical behavior, subclassification is important for histopathologic recognition and diagnosis. The table presents a comparison of histologic features among the four major subtypes of malignant melanoma (",
"    <a class=\"graphic graphic_table graphicRef57168 \" href=\"UTD.htm?9/0/9228\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Superficial spreading melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superficial spreading melanoma is the most common subtype, comprising approximately 75 percent of all malignant melanomas. One-fourth of superficial spreading melanomas are found in association with a preexisting nevus, such as a dysplastic or congenital nevus, while the majority appear to arise de novo. These melanomas derive their name from histologic evidence of lateral (radial) growth for a period of time before vertical (invasive) growth occurs. Although superficial spreading melanoma has a predilection for the back in men and lower extremities in women, it can occur in any anatomic location, and at any age.",
"   </p>",
"   <p>",
"    Clinically, the superficial spreading type of melanoma appears as a variably pigmented plaque with an irregular border, ranging from a few millimeters to several centimeters in diameter (",
"    <a class=\"graphic graphic_picture graphicRef57466 \" href=\"UTD.htm?28/40/29326\">",
"     picture 6",
"    </a>",
"    ). In fully evolved lesions, multiple shades of red, tan, brown, blue, black, gray, and white can be appreciated. The red zones are thought to represent areas of vessel ectasia and inflammation, and the white and gray regions reflect amelanotic or regressed foci. An asymmetric flare at the lesion periphery represents the advancing border of proliferating, neoplastic melanocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=see_link\">",
"     \"Skin examination and clinical features of melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically, superficial spreading melanomas are asymmetric, poorly circumscribed, and lack cellular maturation (ie, the nests and cells do not become smaller as they descend into the reticular dermis) (",
"    <a class=\"graphic graphic_picture graphicRef62540 \" href=\"UTD.htm?34/0/34820\">",
"     picture 7",
"    </a>",
"    ). Typically, the intraepidermal component extends laterally for more than three rete ridges past the confines of the dermal component [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the radial phase of growth, there is haphazard growth of neoplastic melanocytes with single-cell spread throughout the layers of the epidermis (",
"    <a class=\"graphic graphic_picture graphicRef62540 \" href=\"UTD.htm?34/0/34820\">",
"     picture 7",
"    </a>",
"    ). This pagetoid spread of neoplastic melanocytes confers an appearance that resembles buckshot scatter. Cytologically, the melanocytes are often epithelioid in morphology, with large round-to-oval nuclei, prominent eosinophilic nucleoli, and ample eosinophilic to amphophilic cytoplasm that is filled with fine melanin granules. Where neoplastic melanocytes form nests, the nests are often poorly formed and not cohesive.",
"   </p>",
"   <p>",
"    A lymphocytic infiltrate is sometimes observed in the underlying papillary dermis; the presence of such an infiltrate in the earliest stages may signal incipient transformation to a microinvasive tumor. In the microinvasive radial growth phase of superficial spreading melanoma, both single-cell dispersal and nests of neoplastic melanocytes can be seen in the papillary dermis. The cytomorphology of these cells is similar to that seen with entirely intraepidermal growth, although the cytoplasm is characteristically more abundant and eosinophilic in the microinvasive radial growth phase. The largest nest in the dermis should not exceed the largest epidermal nest in size, and dermal mitoses should be absent.",
"   </p>",
"   <p>",
"    Transition to vertical growth phase occurs when the largest nest in the dermis exceeds that in the epidermis, or if mitoses become evident within the dermis. Superficial spreading melanomas in vertical growth phase may be confused with nodular malignant melanoma. The presence of an epidermal component extending three rete ridges beyond the dermal component distinguishes vertical growth phase superficial spreading melanoma from nodular malignant melanoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Lentigo maligna melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lentigo maligna melanoma most commonly arises in sun-damaged areas of the skin in older individuals, and begins as a freckle-like tan-brown macule [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/15\">",
"     15",
"    </a>",
"    ]. The lesion gradually enlarges and develops darker, asymmetric foci (",
"    <a class=\"graphic graphic_picture graphicRef62105 \" href=\"UTD.htm?4/54/4967\">",
"     picture 8",
"    </a>",
"    ). When the lesion is confined to the epidermis (MMIS-lentigo maligna type), it presents as a nonpalpable macule. Approximately 5 percent of intraepidermal lesions evolve to become clinically palpable, signaling dermal invasion and transformation into lentigo maligna melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/16\">",
"     16",
"    </a>",
"    ]. Transformation is slow, and the lesion may be present for 10 to 50 years before a vertical growth phase becomes apparent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Partial regression is not uncommon during evolution, a phenomenon that is represented by foci of blue-gray or light gray coloration. Once a lentigo maligna melanoma is fully evolved, color variegation can be striking.",
"   </p>",
"   <p>",
"    Histologically, neoplastic melanocytes are arrayed along the dermal-epidermal junction in a lentiginous pattern against a background of epidermal atrophy and solar elastosis (",
"    <a class=\"graphic graphic_picture graphicRef73737 \" href=\"UTD.htm?30/25/31122\">",
"     picture 9",
"    </a>",
"    ). During the radial growth phase, the atypical melanocytes are usually polygonal in shape with hyperchromatic, angulated nuclei, and they are dispersed along the dermal-epidermal junction as well as along eccrine ducts and the outer root sheath epithelium of hair follicles. Multinucleated giant melanocytes (\"star-burst giant cells\") may be present at the basal layer of the epidermis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/17\">",
"     17",
"    </a>",
"    ]. These multinucleated giant cells can contain up to 30 nuclei, and their atypical morphology is similar to those in the lentiginous array.",
"   </p>",
"   <p>",
"    As the lesion progresses, poorly cohesive or dyshesive nests are seen along the dermal-epidermal junction, and they are aligned parallel to the long axis of the epidermis, forming the \"swallow's nest\" sign. Pagetoid spread, the confluence of melanocytes along the basal layer, and nesting all herald an incipient invasive phase [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hallmark of the vertical growth phase is the formation of dermal nodules and fascicles that are larger than the epidermal component. The melanocytes are often pleomorphic with variably hyperchromatic nuclei. The cytoplasm of the tumor cells is shrunken and surrounds a pale nucleus with small nucleoli. Numerous mitoses and exuberant pagetoid spread are frequently observed. The lentiginous proliferation extends down the external root sheath of hair follicles, a feature that accounts for the high recurrence rates when these lesions are superficially ablated. Other accompanying features include a lymphocytic infiltrate and the presence of melanophages. The invasive dermal component of lentigo maligna melanoma may assume a spindle cell appearance with background desmoplastic stroma. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Desmoplastic melanoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Acral lentiginous melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acral lentiginous melanomas are the least common variant of radial growth phase melanomas, comprising fewer than 5 percent of all melanomas. They arise most commonly on palmar, plantar, subungual, and occasionally, mucosal surfaces. The acral lentiginous subtype is the most common type of malignant melanoma among Asians and dark-skinned individuals, with a particular predilection for the soles of the feet.",
"   </p>",
"   <p>",
"    Subungual melanoma arises from the nail matrix and usually presents as a longitudinal brown or black band, with or without nail dystrophy. The involvement of the proximal nail fold (Hutchinson&rsquo;s sign) is considered a clue to the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/17\">",
"     17",
"    </a>",
"    ]. Sometimes the presentation is that of a subungual mass (with or without pigmentation) with various degrees of ulceration and nail plate destruction (onychodystrophy) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Not all melanomas arising in acral sites are acral lentiginous melanomas. Four histologic patterns may be seen in melanomas arising on the acral surfaces: acral lentiginous melanoma, nodular melanoma, superficial spreading melanoma, and an unclassified type. In a histologic study of 62 cases of plantar melanoma from Japan, 14 percent were classified as nodular melanoma and 3 percent as superficial spreading melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinically, an acral lentiginous melanoma appears as a dark brown to black, unevenly pigmented patch (",
"    <a class=\"graphic graphic_picture graphicRef78826 \" href=\"UTD.htm?0/3/54\">",
"     picture 10",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/20\">",
"     20",
"    </a>",
"    ]. Areas of regression manifest as foci of gray-white discoloration. If a lesion becomes raised or develops ulceration, the likelihood of invasion should be considered. However, some tumors which invade along the peri-eccrine adventitial dermis may appear flat clinically even if they have encroached upon subcutaneous adipose tissue.",
"   </p>",
"   <p>",
"    Histologically, early acral lentiginous melanomas are characterized by a lentiginous array of atypical melanocytes along the dermal-epidermal junction, with foci of confluent melanocytic growth (",
"    <a class=\"graphic graphic_picture graphicRef82287 \" href=\"UTD.htm?3/31/3576\">",
"     picture 11",
"    </a>",
"    ). With progression, large junctional nests that are composed of atypical melanocytes form, and atypical single cells extend into the epidermis (pagetoid spread) independently of the junctional nests. Confluence of junctional nests frequently heralds microinvasion of single cells into the papillary dermis during the radial growth phase. Invasive lesions are characterized by the presence of neoplastic single cells or nests in the dermis.",
"   </p>",
"   <p>",
"    Cytologically, the lentiginous array of atypical cells is composed of large, hyperchromatic, angulated melanocytes with scant cytoplasm. Prominent dendritic processes highlighted by fine melanin granules extend into the stratum spinosum. Single cells that spread upward into the epidermis in a pagetoid fashion appear epithelioid, like those seen in superficial spreading melanomas. The junctional nests are large with marked loss of cohesiveness, and they contain cells of epithelioid or spindle shape, and severe nuclear atypia.",
"   </p>",
"   <p>",
"    In invasive lesions, the morphology of neoplastic single cells or nests is similar to that of the epidermal component, except their cytoplasm is more abundant with fine pigmentation. Two useful histologic features can help with the distinction of acral lentiginous melanomas from benign acral nevi:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The predominance of a single-cell over a nested pattern; the converse is observed for benign acral nevi",
"     </li>",
"     <li>",
"      The presence of a lichenoid inflammatory infiltrate composed of lymphocytes admixed with melanophages, a feature that is virtually absent in benign acral nevi",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nodular melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, nodular melanomas are vertical growth phase melanomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/21\">",
"     21",
"    </a>",
"    ]. They comprise 15 to 30 percent of all melanomas. Clinically, a nodular melanoma appears as a darkly pigmented, pedunculated or polypoid nodule (",
"    <a class=\"graphic graphic_picture graphicRef80955 \" href=\"UTD.htm?29/25/30110\">",
"     picture 12",
"    </a>",
"    ), although amelanotic variants are infrequently seen [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, dermal growth occurs in isolation or, occasionally, in association with an epidermal component (",
"    <a class=\"graphic graphic_picture graphicRef57679 \" href=\"UTD.htm?27/57/28563\">",
"     picture 13",
"    </a>",
"    ). When an epidermal component is present, it must not extend beyond three rete ridges of the dermal component. The neoplastic cells within the dermal growth may appear epithelioid or spindled. Mitoses are frequent and often atypical.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     RARE VARIANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The challenge of correctly diagnosing certain types of melanoma is due, in part, to their mimicry of benign lesions. As many as seventeen rare variants of malignant melanoma have been described in the last few decades, and new variants continue to emerge. In this section, we will emphasize nevoid melanoma and desmoplastic melanoma, variants that can escape the attention of even the most skilled pathologist because of their resemblance to nonpathologic conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Nevoid melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nevoid melanomas are frequently mistaken for benign dermal nevi because of their superficial resemblance to this lesion, both clinically and histologically. However, nevoid melanoma behaves as a variant of malignant melanoma with metastatic potential [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Clinically, these lesions appear as verrucous or dome-shaped nodules, frequently present on the trunk or proximal limbs of young adults [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologically, nevoid melanoma resembles a dermal nevus in that it lacks a prominent intraepidermal component and has a rather bland dermal component (",
"    <a class=\"graphic graphic_picture graphicRef67103 \" href=\"UTD.htm?7/16/7427\">",
"     picture 14A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/26\">",
"     26",
"    </a>",
"    ]. However, careful inspection reveals that the dermal component has properties of frank vertical growth phase melanoma. On medium power view, it can be seen that the dermal component has striking hypercellularity and hyperchromasia, and the neoplastic nevoid cells lack true maturation, but instead display a phenomenon termed \"pseudomaturation\" (",
"    <a class=\"graphic graphic_picture graphicRef77882 \" href=\"UTD.htm?12/37/12889\">",
"     picture 14B",
"    </a>",
"    ). With higher power magnification, the nevoid cells appear to become smaller in the deeper dermis (as is observed with true maturation of melanocytes in benign nevi), but the cells are very hyperchromatic and are malignant appearing, with readily observed mitoses. Immunohistochemical studies using proliferation antigens and HMB-45 can aid in diagnosis of nevoid melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/26\">",
"     26",
"    </a>",
"    ]. Fluorescent in situ hybridization may also be useful for distinguishing between this variant of melanoma and benign nevi. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Fluorescence in situ hybridization'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Two variants of nevoid melanoma are recognized; one is composed of large, epithelioid cells resembling the cells of a Spitz nevus (a red-pink, isolated, dome-shaped papule or nodule that usually occurs in young children and is composed of large plump cells with pink-blue cytoplasm) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/27\">",
"     27",
"    </a>",
"    ]. The other variant is composed of small nevus-like cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Desmoplastic melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoplastic melanoma is frequently clinically mistaken for a scar, fibroma, fibromatosis, or basal cell carcinoma because it typically presents as an amelanotic, pale, fleshy nodule or plaque that is reminiscent of a scar [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/28\">",
"     28",
"    </a>",
"    ]. The presence of mucin within the lesion may impart a boggy quality [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/29\">",
"     29",
"    </a>",
"    ]. When present, an important clue to clinical diagnosis is the presence of cutaneous pigmentation over a dermal nodule [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/30\">",
"     30",
"    </a>",
"    ]. Desmoplastic melanomas tend to occur on sun-exposed areas of the head, neck, or upper back of older individuals, in whom they sometimes arise in the context of an associated lentigo maligna. In one series of 33 patients with desmoplastic melanoma, eight (24 percent) were associated with lentigo maligna [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic examination reveals a poorly circumscribed, vertical growth phase tumor. The spindle-shaped malignant cells are associated with a marked fibrogenic (myxoid) stromal response, in which reactive fibroblasts are intimately associated with the malignant melanocytes (",
"    <a class=\"graphic graphic_picture graphicRef52697 \" href=\"UTD.htm?8/28/8648\">",
"     picture 15",
"    </a>",
"    ). The malignant cells contain hyperchromatic, elongated nuclei, and their morphology closely resembles that of fibroblasts seen in a scar or fibroma. The hyperchromatic spindle cells form long fascicles that are arranged in acute angles to the horizontal axis of the epidermis; occasionally, single dispersed spindle cells are also observed [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Associated pathologic findings may be helpful in confirming the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The epidermis may contain lentiginous melanocytic hyperplasia or even lentigo maligna [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The spindle-shaped malignant melanocytes may be neurotropic",
"     </li>",
"     <li>",
"      Foci of lymphocyte aggregates and mucin may be seen in the dermis [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Immunohistochemical staining with S-100 is positive, while HMB-45 is generally negative (See",
"      <a class=\"local\" href=\"#H20412808\">",
"       'Immunohistochemistry'",
"      </a>",
"      below.) [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some desmoplastic melanomas fail to stain positively or stain only weakly with S-100 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. A variable proportion expresses the p75 nerve growth factor receptor (P75 NGF-R) [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/36-39\">",
"     36-39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the cytomorphology of desmoplastic melanoma mimics benign fibroblasts, inadequate surgical excision may be performed, contributing to a high recurrence rate. The presence of neurotropism also increases the likelihood of recurrent disease, presumably because tumor cells extend along nerves to outside the wide local excision margin [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features of desmoplastic melanoma are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\", section on 'Desmoplastic melanoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clear cell sarcoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;While technically a sarcoma and not a variant of melanoma, clear cell sarcoma is included in this discussion for its histopathologic similarity to melanoma. Clear cell sarcoma (CCS), or \"melanoma of soft parts\", was initially described in 1965 [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/41\">",
"     41",
"    </a>",
"    ]. For many years, due to the occasional presence of melanin pigment and melanosomes, CCS was thought to be histogenetically related to melanoma. However, CCS bears only a phenotypic resemblance to malignant melanoma. Subsequent genetic studies have demonstrated a characteristic translocation [t(12;22)(q13;q13)], which results in a unique fusion gene that is not found in cutaneous or uveal malignant melanomas, but instead, related to those found in some sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=see_link&amp;anchor=H21#H21\">",
"     \"Pathogenetic factors in soft tissue and bone sarcomas\", section on 'Clear cell sarcoma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CCS typically affects young women in their thirties, and has a predilection for the lower extremities. Although a potentially aggressive tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/43\">",
"     43",
"    </a>",
"    ], its clinical course is usually more indolent than most malignant melanomas.",
"   </p>",
"   <p>",
"    Grossly, CCS often appears fleshy and white, bearing more resemblance to a soft tissue sarcoma than a melanoma. Histologic examination reveals large, polygonal cells with clear to eosinophilic cytoplasm and prominent nucleoli. The cells frequently have an eccentrically located nucleus, conferring a \"plasmacytoid\" appearance; binucleation is also observed.",
"   </p>",
"   <p>",
"    Although the presence of melanin can be demonstrated by special stains in most cases of CCS, melanin is rarely seen on H&amp;E stained sections [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/44\">",
"     44",
"    </a>",
"    ]. Confirmation of the presence of melanin is helpful in distinguishing CCS from other soft tissue sarcomas, especially fibrosarcoma and synovial sarcoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227072#H12227072\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Histopathology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunohistochemically, 80 percent of CCS express S-100, while 78 percent are HMB-45-positive, 75 percent are Mitf-positive, and cytokeratin stains are negative [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/45,46\">",
"     45,46",
"    </a>",
"    ] (See",
"    <a class=\"local\" href=\"#H20412808\">",
"     'Immunohistochemistry'",
"    </a>",
"    below.).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Solitary dermal melanoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Solitary dermal melanoma is a lesion that is confined to the dermis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    subcutaneous tissue, without an epidermal component [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/47\">",
"     47",
"    </a>",
"    ]. Whether these lesions represent a true primary lesion, a dermal metastasis from an unknown primary or a lesion in which the epidermal component has regressed is unknown.",
"   </p>",
"   <p>",
"    The largest reported series included 101 patients, which represented 0.8 percent of the melanoma cases seen at a single institution over a 35 year period [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/47\">",
"     47",
"    </a>",
"    ]. Nine of these patients had distant metastases at presentation. Nodal disease was either present at diagnosis or subsequently developed in 21 of the 92 who did not have disseminated disease at presentation (23 percent). The five-year overall survival rates for those with local and regional disease were 73 and 67 percent, respectively.",
"   </p>",
"   <p>",
"    The observed prognosis in these patients is similar to that of intermediate thickness primary melanomas and suggests that an aggressive approach to initial management, including wide local excision and sentinel lymph node biopsy, is warranted. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"     \"Initial surgical management of melanoma of the skin and unusual sites\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CUTANEOUS MELANOMA METASTASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant melanoma is thought to metastasize first to the regional lymph nodes and then to secondary sites, most commonly skin, subcutaneous soft tissue, lung, and brain. Clinically, metastatic melanoma involving the skin appears as a dermal nodule or plaque-like lesion, often in close proximity to the primary tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link&amp;anchor=H9#H9\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\", section on 'Satellite lesions and in transit metastases'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Histologically, cutaneous metastases appear as nodules in the dermis or subcutaneous fat without an epidermal connection (",
"    <a class=\"graphic graphic_picture graphicRef54296 \" href=\"UTD.htm?5/6/5217\">",
"     picture 16",
"    </a>",
"    ). The cells comprising the dermal nodules commonly have an epithelioid cytomorphology with hyperchromasia. The degree of cellular atypia is variable and is generally similar to the primary melanoma. A significant inflammatory response is typically absent [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the majority of cutaneous metastases have no epidermal connection, epidermal involvement mat be seen rarely, a phenomenon termed epidermotropic metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/50\">",
"     50",
"    </a>",
"    ]. The distinction between an epidermotropic metastasis and a primary malignant melanoma can be challenging. Correlation with clinical data, especially a careful search for a primary melanoma, is important.",
"   </p>",
"   <p>",
"    Certain histologic features that are more consistently observed in epidermotropic metastases can help in the differentiation from primary cutaneous melanoma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The dermal component of epidermotropic metastases extends laterally beyond the borders of the epidermal involvement, while the opposite is often observed in primary melanomas. The epidermis also tends to be atrophic in metastatic melanomas.",
"     </li>",
"     <li>",
"      Although the cytomorphology of malignant melanocytes in the dermis is similar to that of the epidermal component in metastatic lesions, the morphology of cells in the epidermal and dermal component of a primary tumor tend to be more disparate.",
"     </li>",
"     <li>",
"      Compared to the frequently observed lichenoid inflammatory response in a primary tumor, this response is rarely appreciated in a metastatic tumor, in the absence of immunotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although rarely seen in primary melanomas, tumors cells within vascular channels are characteristic of metastatic melanomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22859673\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF MELANOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histopathology is the gold standard of diagnosis (",
"    <a class=\"graphic graphic_table graphicRef57168 \" href=\"UTD.htm?9/0/9228\">",
"     table 1",
"    </a>",
"    ). In difficult cases immunohistochemistry or fluorescence in situ hybridization may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Components of the pathology report",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to confirming the diagnosis, pathologic evaluation provides important prognostic information that helps direct management, and this information must be provided to the clinician [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/2\">",
"     2",
"    </a>",
"    ]. Once the diagnosis of malignant melanoma is established, the pathology report must include the subtype and a description of cytomorphology and architecture. Other important prognostic factors should be included, such as the greatest thickness, anatomic or Clark's level, presence of ulceration, margin status, and for vertical growth phase lesions, the presence of mitoses, lymphocytic infiltrates, microsatellites and neural or vascular invasion (",
"    <a class=\"graphic graphic_table graphicRef53455 \" href=\"UTD.htm?17/30/17899\">",
"     table 2",
"    </a>",
"    ). An example of the histology worksheet used at our institution is presented in the following table (",
"    <a class=\"graphic graphic_figure graphicRef65104 \" href=\"UTD.htm?19/45/20176\">",
"     figure 1",
"    </a>",
"    ). A detailed discussion of prognostic factors in melanoma is provided elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20412808\">",
"    <span class=\"h2\">",
"     Immunohistochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunohistochemistry can be helpful in difficult cases or in nodal metastases. The most widely used markers are S-100, MART-1, and HMB-45 (",
"    <a class=\"graphic graphic_table graphicRef68372 \" href=\"UTD.htm?21/38/22124\">",
"     table 3",
"    </a>",
"    ). The role of immunohistochemistry in both primary lesions and lymph nodes is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1206?source=see_link&amp;anchor=H1000645#H1000645\">",
"     \"Pathologic evaluation of regional lymph nodes in melanoma\", section on 'Immunohistochemistry'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fluorescence in situ hybridization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies suggest that fluorescent in situ hybridization (FISH) may be a useful technique for the pathologic diagnosis of melanoma [",
"    <a class=\"abstract\" href=\"UTD.htm?21/31/22009/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. The procedure involves the cytogenetic analysis of melanocytic neoplasms through the detection of chromosomal aberrations. FISH may be particularly useful in cases in which the diagnosis of melanoma is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21647592\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pathologic report provides diagnostic and prognostic information that influence the selection of treatment for patients with melanoma (",
"      <a class=\"graphic graphic_table graphicRef53455 \" href=\"UTD.htm?17/30/17899\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26207195\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Components of the pathology report'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Melanomas exhibit two growth modalities, the radial and the vertical phase. In the radial growth phase, proliferation of malignant melanocytes is confined to the epidermis or the upper dermis. In the vertical growth phase malignant melanocytes form nests or nodules in the dermis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Growth phases of melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Four principal histologic types of melanoma are recognized: superficial spreading melanoma, lentigo maligna melanoma, acral lentiginous melanoma, and nodular melanoma. For each type, except the nodular, an in situ form exists. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Major subtypes of invasive melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Superficial spreading melanoma appears as a plaque that is a few millimeters to several centimeters in diameter, with irregular borders and variegated color (",
"      <a class=\"graphic graphic_picture graphicRef57466 \" href=\"UTD.htm?28/40/29326\">",
"       picture 6",
"      </a>",
"      ). Malignant melanocytes spread throughout the layers of the epidermis as single cells and nests. In the vertical growth phase, mitoses or nests of malignant melanocytes are observed in the dermis (",
"      <a class=\"graphic graphic_picture graphicRef62540 \" href=\"UTD.htm?34/0/34820\">",
"       picture 7",
"      </a>",
"      ). The melanocytes are epithelioid with large nuclei and abundant cytoplasm filled with melanin granules. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Superficial spreading melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lentigo maligna melanomas begin as a nonpalpable tan or brown macule, enlarging gradually over many years (",
"      <a class=\"graphic graphic_picture graphicRef62105 \" href=\"UTD.htm?4/54/4967\">",
"       picture 8",
"      </a>",
"      ). Dermal invasion is signaled by the appearance of palpable areas. Neoplastic melanocytes are polygonal with hyperchromatic nuclei, arrayed along the dermal-epidermal junction in a lentiginous pattern (",
"      <a class=\"graphic graphic_picture graphicRef73737 \" href=\"UTD.htm?30/25/31122\">",
"       picture 9",
"      </a>",
"      ). A dermal nodule indicates a vertical growth phase. The cells appear pleomorphic, with shrunken cytoplasm, and extend down the external root sheath of hair follicles. Desmoplastic melanoma may arise in conjunction with lentigo maligna. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Lentigo maligna melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acral lentiginous melanomas arise on palmar, plantar, subungual, and mucosal surfaces (",
"      <a class=\"graphic graphic_picture graphicRef78826 \" href=\"UTD.htm?0/3/54\">",
"       picture 10",
"      </a>",
"      ). Atypical melanocytes are arrayed along the dermal-epidermal junction (",
"      <a class=\"graphic graphic_picture graphicRef82287 \" href=\"UTD.htm?3/31/3576\">",
"       picture 11",
"      </a>",
"      ). Progression is marked by the presence of large junctional nests of atypical melanocytes, which are large, hyperchromatic with scant cytoplasm. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Acral lentiginous melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nodular melanomas are by definition vertical growth phase melanomas. They present as darkly pigmented nodules, sometimes ulcerated (",
"      <a class=\"graphic graphic_picture graphicRef80955 \" href=\"UTD.htm?29/25/30110\">",
"       picture 12",
"      </a>",
"      ). On histology, there is a nodule of neoplastic cells in the dermis, with no recognizable adjacent radial growth phase (",
"      <a class=\"graphic graphic_picture graphicRef57679 \" href=\"UTD.htm?27/57/28563\">",
"       picture 13",
"      </a>",
"      ). The neoplastic melanocytes are epithelioid or spindle cells; mitoses are frequent and often atypical. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Nodular melanoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rare variants of melanoma include nevoid melanoma (",
"      <a class=\"graphic graphic_picture graphicRef67103 graphicRef77882 \" href=\"UTD.htm?24/45/25306\">",
"       picture 14A-B",
"      </a>",
"      ), desmoplastic melanoma (",
"      <a class=\"graphic graphic_picture graphicRef52697 \" href=\"UTD.htm?8/28/8648\">",
"       picture 15",
"      </a>",
"      ), and solitary dermal melanoma. Clear cell sarcoma may closely resemble melanoma microscopically. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Rare variants'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Metastatic melanoma involving the skin appears as a dermal nodule or plaque-like lesion, often in close proximity to the primary tumor. Histologically, cutaneous metastases appear as nodules in the dermis or subcutaneous fat without an epidermal connection (",
"      <a class=\"graphic graphic_picture graphicRef54296 \" href=\"UTD.htm?5/6/5217\">",
"       picture 16",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cutaneous melanoma metastases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most melanomas are diagnosed on routine histology. Immunohistochemistry can be helpful in difficult cases or in nodal metastases. The most widely used markers are S-100, MART-1, and HMB-45. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1206?source=see_link&amp;anchor=H1000645#H1000645\">",
"       \"Pathologic evaluation of regional lymph nodes in melanoma\", section on 'Immunohistochemistry'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/2\">",
"      Liu V, Mihm MC. Pathology of malignant melanoma. Surg Clin North Am 2003; 83:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/3\">",
"      Bastian BC. Understanding the progression of melanocytic neoplasia using genomic analysis: from fields to cancer. Oncogene 2003; 22:3081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/4\">",
"      Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res 2000; 60:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/5\">",
"      Clark WH Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/6\">",
"      Bedrosian I, Faries MB, Guerry D 4th, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (&lt; or = 1 mm) with vertical growth phase. Ann Surg Oncol 2000; 7:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/7\">",
"      Satyamoorthy K, DeJesus E, Linnenbach AJ, et al. Melanoma cell lines from different stages of progression and their biological and molecular analyses. Melanoma Res 1997; 7 Suppl 2:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/8\">",
"      Boukerche H, Baril P, Tabone E, et al. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype. Cancer Res 2000; 60:5848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/9\">",
"      Clark WH Jr, Elder DE, Guerry D 4th, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989; 81:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/10\">",
"      Tannous ZS, Lerner LH, Duncan LM, et al. Progression to invasive melanoma from malignant melanoma in situ, lentigo maligna type. Hum Pathol 2000; 31:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/11\">",
"      Elder DE, Guerry D 4th, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984; 6 Suppl:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/12\">",
"      Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/13\">",
"      McGovern VJ, Mihm MC Jr, Bailly C, et al. The classification of malignant melanoma and its histologic reporting. Cancer 1973; 32:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/14\">",
"      Jelfs PL, Giles G, Shugg D, et al. Cutaneous malignant melanoma in Australia, 1989. Med J Aust 1994; 161:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/15\">",
"      Clark WH Jr, Mihm MC Jr. Lentigo maligna and lentigo-maligna melanoma. Am J Pathol 1969; 55:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/16\">",
"      Weinstock MA, Sober AJ. The risk of progression of lentigo maligna to lentigo maligna melanoma. Br J Dermatol 1987; 116:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/17\">",
"      Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/18\">",
"      Buka R, Friedman KA, Phelps RG, et al. Childhood longitudinal melanonychia: case reports and review of the literature. Mt Sinai J Med 2001; 68:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/19\">",
"      Kato T, Suetake T, Tabata N, et al. Epidemiology and prognosis of plantar melanoma in 62 Japanese patients over a 28-year period. Int J Dermatol 1999; 38:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/20\">",
"      Coleman WP 3rd, Loria PR, Reed RJ, Krementz ET. Acral lentiginous melanoma. Arch Dermatol 1980; 116:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/21\">",
"      Clark WH Jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol 1986; 17:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/22\">",
"      Plotnick H, Rachmaninoff N, VandenBerg HJ Jr. Polypoid melanoma: a virulent variant of nodular melanoma. Report of three cases and literature review. J Am Acad Dermatol 1990; 23:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/23\">",
"      Wong TY, Suster S, Duncan LM, Mihm MC Jr. Nevoid melanoma: a clinicopathological study of seven cases of malignant melanoma mimicking spindle and epithelioid cell nevus and verrucous dermal nevus. Hum Pathol 1995; 26:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/24\">",
"      Gamblin TC, Edington H, Kirkwood JM, Rao UN. Sentinel lymph node biopsy for atypical melanocytic lesions with spitzoid features. Ann Surg Oncol 2006; 13:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/25\">",
"      Schmoeckel C, Castro CE, Braun-Falco O. Nevoid malignant melanoma. Arch Dermatol Res 1985; 277:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/26\">",
"      McNutt NS, Urmacher C, Hakimian J, et al. Nevoid malignant melanoma: morphologic patterns and immunohistochemical reactivity. J Cutan Pathol 1995; 22:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/27\">",
"      Lee DA, Cohen JA, Twaddell WS, et al. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma. Cancer 2006; 106:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/28\">",
"      Conley J, Lattes R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971; 28:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/29\">",
"      Bruijn JA, Mihm MC Jr, Barnhill RL. Desmoplastic melanoma. Histopathology 1992; 20:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/30\">",
"      Wharton JM, Carlson JA, Mihm MC Jr. Desmoplastic malignant melanoma: diagnosis of early clinical lesions. Hum Pathol 1999; 30:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/31\">",
"      Su LD, Fullen DR, Lowe L, et al. Desmoplastic and neurotropic melanoma. Cancer 2004; 100:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/32\">",
"      Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma. A clinicopathologic analysis of 28 cases. Cancer 1995; 75:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/33\">",
"      Chorny JA, Barr RJ. S100-positive spindle cells in scars: a diagnostic pitfall in the re-excision of desmoplastic melanoma. Am J Dermatopathol 2002; 24:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/34\">",
"      Anstey A, Cerio R, Ramnarain N, et al. Desmoplastic malignant melanoma. An immunocytochemical study of 25 cases. Am J Dermatopathol 1994; 16:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/35\">",
"      Argenyi ZB, Cain C, Bromley C, et al. S-100 protein-negative malignant melanoma: fact or fiction? A light-microscopic and immunohistochemical study. Am J Dermatopathol 1994; 16:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/36\">",
"      Kanik AB, Yaar M, Bhawan J. p75 nerve growth factor receptor staining helps identify desmoplastic and neurotropic melanoma. J Cutan Pathol 1996; 23:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/37\">",
"      Lazova R, Tantcheva-Poor I, Sigal AC. P75 nerve growth factor receptor staining is superior to S100 in identifying spindle cell and desmoplastic melanoma. J Am Acad Dermatol 2010; 63:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/38\">",
"      Iwamoto S, Burrows RC, Agoff SN, et al. The p75 neurotrophin receptor, relative to other Schwann cell and melanoma markers, is abundantly Expressed in spindled melanomas. Am J Dermatopathol 2001; 23:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/39\">",
"      Huttenbach Y, Prieto VG, Reed JA. Desmoplastic and spindle cell melanomas express protein markers of the neural crest but not of later committed stages of Schwann cell differentiation. J Cutan Pathol 2002; 29:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/40\">",
"      Quinn MJ, Crotty KA, Thompson JF, et al. Desmoplastic and desmoplastic neurotropic melanoma: experience with 280 patients. Cancer 1998; 83:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/41\">",
"      ENZINGER FM. CLEAR-CELL SARCOMA OF TENDONS AND APONEUROSES. AN ANALYSIS OF 21 CASES. Cancer 1965; 18:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/42\">",
"      Fujimura Y, Siddique H, Lee L, et al. EWS-ATF-1 chimeric protein in soft tissue clear cell sarcoma associates with CREB-binding protein and interferes with p53-mediated trans-activation function. Oncogene 2001; 20:6653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/43\">",
"      Jacobs IA, Chang CK, Guzman G, Salti GI. Clear cell sarcoma: an institutional review. Am Surg 2004; 70:300.",
"     </a>",
"    </li>",
"    <li>",
"     Enzinger FM, Weiss SW. Soft tissue tumors, 5th ed, Mosby Elsevier, St. Louis 2008. p.930.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/45\">",
"      Granter SR, Weilbaecher KN, Quigley C, et al. Clear cell sarcoma shows immunoreactivity for microphthalmia transcription factor: further evidence for melanocytic differentiation. Mod Pathol 2001; 14:6.",
"     </a>",
"    </li>",
"    <li>",
"     Kempson RL, Fletcher CDM, Evans HL, et al. Tumors of the soft tissues. In: Atlas of tumor pathology, Armed Forces Institute of Pathology, Washington DC 2001. Vol 463.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/47\">",
"      Lee CC, Faries MB, Ye X, Morton DL. Solitary dermal melanoma: beginning or end of the metastatic process? Ann Surg Oncol 2009; 16:578.",
"     </a>",
"    </li>",
"    <li>",
"     Elder DE. Metastic melanoma. In: Pathobiology of Malignant Melanoma, Elder DE (Ed), S Karger AG, Basel, Switzerland 1987. p.182.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/49\">",
"      Mihm MC Jr, Clemente CG, Cascinelli N. Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996; 74:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/50\">",
"      Abernethy JL, Soyer HP, Kerl H, et al. Epidermotropic metastatic malignant melanoma simulating melanoma in situ. A report of 10 examples from two patients. Am J Surg Pathol 1994; 18:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/51\">",
"      Gerami P, Mafee M, Lurtsbarapa T, et al. Sensitivity of fluorescence in situ hybridization for melanoma diagnosis using RREB1, MYB, Cep6, and 11q13 probes in melanoma subtypes. Arch Dermatol 2010; 146:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?21/31/22009/abstract/52\">",
"      Gerami P, Wass A, Mafee M, et al. Fluorescence in situ hybridization for distinguishing nevoid melanomas from mitotically active nevi. Am J Surg Pathol 2009; 33:1783.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4843 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22009=[""].join("\n");
var outline_f21_31_22009=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21647592\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26207195\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GROWTH PHASES OF MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radial growth phase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - In situ melanoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Microinvasive radial growth phase melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Vertical growth phase",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      MAJOR SUBTYPES OF INVASIVE MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Superficial spreading melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Lentigo maligna melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Acral lentiginous melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nodular melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RARE VARIANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Nevoid melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Desmoplastic melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clear cell sarcoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Solitary dermal melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CUTANEOUS MELANOMA METASTASES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22859673\">",
"      DIAGNOSIS OF MELANOMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Components of the pathology report",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20412808\">",
"      Immunohistochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fluorescence in situ hybridization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21647592\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/4843\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4843|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/45/20176\" title=\"figure 1\">",
"      Melanoma pathology worksheet",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4843|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/2/42020\" title=\"picture 1\">",
"      Histol radial growth melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/61/24534\" title=\"picture 2\">",
"      Histol melan in situ sup spread",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/57/6037\" title=\"picture 3\">",
"      Histol melanoma in situ lentigo",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/6/19557\" title=\"picture 4\">",
"      Histol microinvasive melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/63/38904\" title=\"picture 5A\">",
"      Vertical growth melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/7/43125\" title=\"picture 5B\">",
"      Histol vertical growth melan 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/40/29326\" title=\"picture 6\">",
"      Superficial spreading melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/0/34820\" title=\"picture 7\">",
"      Histol superfic spread melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/54/4967\" title=\"picture 8\">",
"      New lentigo maligna melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/25/31122\" title=\"picture 9\">",
"      Histol lentigo maligna melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/3/54\" title=\"picture 10\">",
"      Acral lentiginous melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?3/31/3576\" title=\"picture 11\">",
"      Histol acral lentig melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/25/30110\" title=\"picture 12\">",
"      Nodular melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/57/28563\" title=\"picture 13\">",
"      Histology nodular melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/16/7427\" title=\"picture 14A\">",
"      Histology nevoid melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/37/12889\" title=\"picture 14B\">",
"      Histology nevoid melanoma 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/28/8648\" title=\"picture 15\">",
"      Histology desmoplastic melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/6/5217\" title=\"picture 16\">",
"      Histology metastatic melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/4843|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/0/9228\" title=\"table 1\">",
"      Compare melanoma subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/30/17899\" title=\"table 2\">",
"      Histopathology report melanoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/38/22124\" title=\"table 3\">",
"      Compare IHC markers melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/39/14970?source=related_link\">",
"      Epidemiology and clinical features of basal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/56/25482?source=related_link\">",
"      Epidemiology and risk factors for cutaneous squamous cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/26/6569?source=related_link\">",
"      Inherited susceptibility to melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32042?source=related_link\">",
"      Pathogenetic factors in soft tissue and bone sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1206?source=related_link\">",
"      Pathologic evaluation of regional lymph nodes in melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/53/24410?source=related_link\">",
"      Risk factors for the development of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/16/16650?source=related_link\">",
"      Screening and early detection of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/20/16713?source=related_link\">",
"      Skin examination and clinical features of melanoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42488?source=related_link\">",
"      Tumor node metastasis (TNM) staging system and other prognostic factors in cutaneous melanoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f21_31_22010="Dermatophyte KOH";
var content_f21_31_22010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60102%7EPC%2F79879%7EPC%2F58965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60102%7EPC%2F79879%7EPC%2F58965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dermatophyte potassium hydroxide preparation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Septate hyphae are visible on a background of squamous cells in this potassium hydroxide preparation taken from a lesion of tinea corporis. Potassium hydroxide preparations from tinea pedis and tinea cruris have a similar appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Candida albicans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 423px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hyphae of",
"    <em>",
"     Candida albicans",
"    </em>",
"    seen on KOH prep with light microscopy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eva Rawlings Parker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microscopic tinea versicolor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 264px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Examination of scale with 10 percent potassium hydroxide reveals both hyphae and spores in the characteristic \"spaghetti and meatballs\" pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Beth G Goldstein, MD and Adam O Goldstein, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22010=[""].join("\n");
var outline_f21_31_22010=null;
var title_f21_31_22011="Celiac screening in children";
var content_f21_31_22011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57975&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of celiac disease in 17,201 Italian school children (age 6 to 15)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgG and/or IgA antigliadin antibodies",
"       </td>",
"       <td>",
"        7.50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IgA antigliadin and/or IgA endomysial antibodies",
"       </td>",
"       <td>",
"        0.65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Intestinal biopsy performed",
"       </td>",
"       <td>",
"        0.57",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Villous atrophy seen on biopsy",
"       </td>",
"       <td>",
"        0.44",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Not biopsied but clinically celiac",
"       </td>",
"       <td>",
"        0.04",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Previously known celiac",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         TOTAL with diagnosis of celiac disease",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.54",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Catassi C, Fabiani E, R&auml;tsch IM, et al. The coeliac iceberg in Italy: a multicentre antigliadin antibodies screening for coeliac disease in school-age subjects. Acta Paediatr 1996; 412(Suppl):29.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22011=[""].join("\n");
var outline_f21_31_22011=null;
var title_f21_31_22012="Personality dis DSM-IV-TR";
var content_f21_31_22012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F69002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F69002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Personality disorders in DSM-IV-TR",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Axis II personality disorders",
"       </td>",
"       <td class=\"subtitle1\">",
"        Key features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cluster A (odd, eccentric)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paranoid",
"       </td>",
"       <td>",
"        Distrust and suspiciousness of others such that their motives are interpreted as malevolent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schizotypal",
"       </td>",
"       <td>",
"        Social and interpersonal deficits marked by acute discomfort with, and reduced capacity for, close relationships as well as by cognitive or perceptual distortions and eccentric behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schizoid",
"       </td>",
"       <td>",
"        Detachment from social relationships and a restricted range of expression of emotions in interpersonal settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cluster B (impulsive, emotional, dramatic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antisocial",
"       </td>",
"       <td>",
"        Failure to respect the rights of others, lying, stealing, defaulting on debts, neglect of children or other dependents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Borderline",
"       </td>",
"       <td>",
"        Instability of interpersonal relationships, self-image, affects, and control over impulses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Histrionic",
"       </td>",
"       <td>",
"        Excessive emotionality and attention seeking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Narcissistic",
"       </td>",
"       <td>",
"        Grandiosity (in fantasy or behavior), need for admiration, and lack of empathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Cluster C (anxious, fearful)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Dependent",
"       </td>",
"       <td>",
"        Feels inadequate, cannot make own decisions, submissive, avoids confrontation for fear of losing source of support",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Avoidant",
"       </td>",
"       <td>",
"        Social discomfort and reticence, feelings of inadequacy, and hypersensitivity to criticism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Obsessive-compulsive",
"       </td>",
"       <td>",
"        Preoccupation with perfectionism, mental and interpersonal control, and orderliness, at the expense of flexibility, openness, and efficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, 2000, Washington, D.C.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22012=[""].join("\n");
var outline_f21_31_22012=null;
var title_f21_31_22013="Hysterosc steriliz protocol";
var content_f21_31_22013=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70591&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hysteroscopic sterilization micro-insert protocol",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Pre-procedure preparation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Review informed consent regarding nonreversible contraception and surgical issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Conduct medical history and physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Prescribe pre-procedure medications (eg, progestin for endometrial preparation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Day of procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Rule out pregnancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Administer ketorolac 30 mg intramuscularly or intravenously (if patient has not taken oral NSAID within 24 hours) to prevent tubal spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Check equipment:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Hysteroscopic sterilization device - two individually wrapped devices (more should be available in case a device is damaged or does not deploy properly)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Rigid hysteroscope - must have either a 12&deg; or a 30&deg; lens, fluid inflow channel, and instrument channel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Hysteroscopic grasper - for use if an errantly deployed device needs to be retrieved from the uterine cavity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Distension fluid - use electrolyte solution (eg, normal saline or lactated Ringer's); use fluid sparingly to avoid fluid overload and endometrial edema that can obscure operative field; manual or automatic system to monitor fluid inflow and deficit; use cystoscopy tubing for better flow",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Procedure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Administer anlagesia and/or anesthesia (type of analgesia or anesthesia will vary by patient or surgeon)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Position and prepare patient for hysteroscopy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Introduce hysteroscope into the endometrial cavity and identify",
"        <strong>",
"         BOTH",
"        </strong>",
"        tubal ostia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\">",
"        Insert and deploy the device:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Open the first device package and insert the introducer sheath into the working channel of the hysteroscope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Position the hysteroscope at one of the tubal ostium while the assistant threads the first device delivery system into the introducer sheath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Take hold of the device handle and guide the tip of the micro-insert through the tubal ostium into the fallopian tube",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Thread the device into the tube until the black marker is positioned at the tubal ostium",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Rotate the thumbwheel towards yourself until it can no longer rotate (this will expose the wound down micro-insert)",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Align the gold marker band just outside the tubal ostium",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Press the deployment button",
"        <br/>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Rotate the thumbwheel towards yourself again until it can no longer rotate (the micro-insert will unwind and detach from the delivery system)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Remove the device delivery system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\" colspan=\"2\">",
"        &bull; Count and record the number of expanded coils extruding from the tubal ostium - ideally, there should be 3 to 8 expanded coils trailing into the uterus; if there are 18 or more expanded coils, remove the micro-insert and re-attempt insertion with a new device",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Repeat the procedure at the contralateral tubal ostium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Discharge patient to home or post-anesthesia care unit",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Follow-up",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Counsel patient to call for fever, excessive vaginal bleeding, severe or persistent pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Advise patient to use contraception until confirmation of correct device placement and bilateral tubal occlusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        At 3 months after procedure, perform hysterosalpingogram to confirm correct placement and bilateral tubal occlusion",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22013=[""].join("\n");
var outline_f21_31_22013=null;
var title_f21_31_22014="Processed EEG brain monitors";
var content_f21_31_22014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F81084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F81084&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Processed EEG brain monitors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Monitor*",
"      </td>",
"      <td class=\"subtitle1\">",
"       Manufacturer&bull;",
"      </td>",
"      <td class=\"subtitle1\">",
"       Parameters",
"      </td>",
"      <td class=\"subtitle1\">",
"       Monitoring range",
"      </td>",
"      <td class=\"subtitle1\">",
"       Notes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Unprocessed EEG",
"      </td>",
"      <td rowspan=\"6\">",
"       Non-proprietary",
"      </td>",
"      <td rowspan=\"6\">",
"       Alpha, beta, gamma, delta, theta waves, sleep spindles; K complexes, spectral edge frequency, burst suppression; Isoelectricity",
"      </td>",
"      <td>",
"       No specific index. Permutation entropy can be derived.",
"      </td>",
"      <td>",
"       <p>",
"        Advantages: rapid response time, cheap, non proprietary.",
"       </p>",
"       <p>",
"        Disadvantages: No index or value, requires attention, requires training.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       High frequency, low amplitude (gamma and beta dominance)",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Alpha oscillations",
"      </td>",
"      <td>",
"       Drowsiness/sedation common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Spindles, K complexes, some delta waves",
"      </td>",
"      <td>",
"       Explicit recall rare",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Slow delta waves, spectral edge &lt;12",
"      </td>",
"      <td>",
"       Surgical anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Burst suppression and isoelectricity",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Bispectral index (BIS)",
"      </td>",
"      <td rowspan=\"6\">",
"       Covidien Medical",
"      </td>",
"      <td rowspan=\"6\">",
"       Bispectral index (proprietary algorithm) based upon beta power, bispectral coherence (synchfastslow), and burst suppression ratio",
"      </td>",
"      <td>",
"       0 to 100",
"      </td>",
"      <td>",
"       <p>",
"        Raw EEG and parameters such as spectral edge frequency can and should be displayed.",
"       </p>",
"       <p>",
"        Advantages: Index value can be used to guide anesthesia. May improve outcomes.",
"       </p>",
"       <p>",
"        Disadvantages: Slow response time, costly, proprietary.",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       80 to 100",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       60 to 80",
"      </td>",
"      <td>",
"       Drowsiness/sedation common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       50 to 60",
"      </td>",
"      <td>",
"       Explicit recall rare",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       30 to 50",
"      </td>",
"      <td>",
"       Surgical anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 30",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       Entropy",
"      </td>",
"      <td rowspan=\"6\">",
"       GE Healthcare",
"      </td>",
"      <td rowspan=\"6\">",
"       State entropy (SE) and response entropy (RE) indices; burst suppression ratio; Entropy of EEG signal decreases with sleep and anesthesia",
"      </td>",
"      <td>",
"       <p>",
"        SE: (0 to 100)",
"       </p>",
"       <p>",
"        RE: (0 to 91)",
"       </p>",
"      </td>",
"      <td>",
"       State entropy (SE)of EEG signal calculated up to 32 Hz. Response entropy (RE) includes additional frequencies up to 47 Hz. SE is always &le;RE. Raw EEG can and should be displayed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       80 to 100",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sudden drop in entropy",
"      </td>",
"      <td>",
"       May be associated with loss of responsiveness",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40 to 60",
"      </td>",
"      <td>",
"       <p>",
"        Explicit recall rare",
"       </p>",
"       <p>",
"        Surgical anesthesia common",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sudden rise in RE",
"      </td>",
"      <td>",
"       May indicate pain or muscle activity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Lower entropy numbers and burst suppression",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       <p>",
"        A-line&reg;",
"       </p>",
"       <p>",
"        AEP Monitor/2&reg;",
"       </p>",
"       <p>",
"        (Adds EEG parameters)",
"       </p>",
"      </td>",
"      <td rowspan=\"6\">",
"       Danmeter a/s",
"      </td>",
"      <td rowspan=\"6\">",
"       Middle latency auditory evoked potentials (MLAEPs); ARX Auditory Index (AAI); Middle latency (20 to 80 msec); Composite AAI Index (Proprietary - combines EEG and MLAEP information)",
"      </td>",
"      <td>",
"       0 to 100",
"      </td>",
"      <td>",
"       Full range",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       60 to 100",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40 to 60",
"      </td>",
"      <td>",
"       Drowsiness/sedation common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25 to 40",
"      </td>",
"      <td>",
"       Light anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       15 to 25",
"      </td>",
"      <td>",
"       Surgical anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 15",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       <p>",
"        Cerebral State&reg;",
"       </p>",
"       <p>",
"        Hand-held device",
"       </p>",
"       <p>",
"        Wireless connection to anesthesia monitor",
"       </p>",
"      </td>",
"      <td rowspan=\"7\">",
"       Danmeter a/s",
"      </td>",
"      <td rowspan=\"7\">",
"       Cerebral State Index (CSI) (Proprietary); Burst suppression electromyography and signal quality are indicated; Index derived mainly from alpha and beta EEG ratios, burst suppression",
"      </td>",
"      <td>",
"       0 to 100",
"      </td>",
"      <td>",
"       Full range",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       90 to 100",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       80 to 90",
"      </td>",
"      <td>",
"       Drowsiness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       60 to 80",
"      </td>",
"      <td>",
"       Light anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       40 to 60",
"      </td>",
"      <td>",
"       Surgical anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 to 40",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 10",
"      </td>",
"      <td>",
"       Burst suppression or isoelectric EEG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"7\">",
"       Narcotrend&reg;",
"      </td>",
"      <td rowspan=\"7\">",
"       MT MonitorTechnik GmbH &amp; Co. KG",
"      </td>",
"      <td rowspan=\"7\">",
"       Cerebrogram (Proprietary); Raw EEG waveform displayed; Median and spectral edge frequencies; Power in EEG frequency bands is shown",
"      </td>",
"      <td>",
"       A to F",
"      </td>",
"      <td>",
"       Full range",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Drowsiness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       Light anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       D",
"      </td>",
"      <td>",
"       Surgical anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       E",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       F",
"      </td>",
"      <td>",
"       Burst suppression or isoelectric EEG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"6\">",
"       SEDline&reg;",
"      </td>",
"      <td rowspan=\"6\">",
"       Hospira",
"      </td>",
"      <td rowspan=\"6\">",
"       Patient state index (PSI) (Proprietary); Raw EEG waveform displayed; Density spectral array (DSA) shown; Converts EEG acquired from four active, ground and reference electrodes into a proprietary index; Anteriorization of EEG power; loss of coherence",
"      </td>",
"      <td>",
"       0 to 100",
"      </td>",
"      <td>",
"       Full range",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       90 to 100",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       50 to 90",
"      </td>",
"      <td>",
"       Drowsiness/sedation common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       25 to 50",
"      </td>",
"      <td>",
"       Surgical anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       10 to 25",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 10",
"      </td>",
"      <td>",
"       Burst suppression or isoelectric EEG",
"      </td>",
"     </tr>",
"     <tr>",
"      <td rowspan=\"5\">",
"       SNAP II&reg;",
"      </td>",
"      <td rowspan=\"5\">",
"       Stryker",
"      </td>",
"      <td rowspan=\"5\">",
"       SNAP index (Proprietary); Spectral analysis of low (0-18 Hz) and high (&gt;80 Hz) frequency EEG components; PDA portable device; Raw EEG waveform displayed",
"      </td>",
"      <td>",
"       0 to 100",
"      </td>",
"      <td>",
"       Full range",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       90 to 100",
"      </td>",
"      <td>",
"       Wakefulness common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       65 to 90",
"      </td>",
"      <td>",
"       Drowsiness/sedation common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       50 to 65",
"      </td>",
"      <td>",
"       Surgical anesthesia common",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       0 to 50",
"      </td>",
"      <td>",
"       Deep anesthesia common",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * All brain monitors are not specific for the anesthetic state. Patient morbidity, drugs and even natural sleep can confound anesthetic depth monitoring.",
"     <br>",
"      &bull; Specific manufacturer guidelines for use may vary.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22014=[""].join("\n");
var outline_f21_31_22014=null;
var title_f21_31_22015="Perforation of TM";
var content_f21_31_22015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65160&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Traumatic tympanic membrane perforation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior canal wall skin is on the left side; the malleus is on the right side. The perforation appears dark and is surrounded by mildly hyperemic smooth edges.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Adele Karen Evans, MD, FAAP and Steven D Handler MD, MBE.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f21_31_22015=[""].join("\n");
var outline_f21_31_22015=null;
